<SEC-DOCUMENT>0001193805-26-000493.txt : 20260422
<SEC-HEADER>0001193805-26-000493.hdr.sgml : 20260422
<ACCEPTANCE-DATETIME>20260422165618
ACCESSION NUMBER:		0001193805-26-000493
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260422
DATE AS OF CHANGE:		20260422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		26884513

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>e665391_10ka-immunic.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:IMUX="http://imux.com/20251231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_IMUX_imux.com_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DDocumentFiscalYearFocus_2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001280776 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000004" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001280776</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="imux-20251231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-04-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-04-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b>&#160;</p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20250101__20251231_zTFO32yS44Vf"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000011" name="dei:DocumentType">10-K/A</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amendment No. 1</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(Mark One)</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--DocumentAnnualReport_c20250101__20251231_zQ9DCNcjNAN5"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000012" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <b><span id="xdx_90F_edei--DocumentPeriodEndDate_c20250101__20251231_zQXzYucsC4Xf"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayyearen" id="Fact000013" name="dei:DocumentPeriodEndDate"><span id="xdx_909_edei--CurrentFiscalYearEndDate_c20250101__20251231_zrbNhe9MpWR1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayen" id="Fact000014" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, 2025</ix:nonNumeric></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--DocumentTransitionReport_c20250101__20251231_z8vysp2z9v7g"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000015" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from <span style="text-decoration: underline">&#160;</span> to
<span style="text-decoration: underline">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <b><span id="xdx_905_edei--EntityFileNumber_c20250101__20251231_zW6pPzoJ3Ckc"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000016" name="dei:EntityFileNumber">001-36201</ix:nonNumeric></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityRegistrantName_c20250101__20251231_zB2M77ouge04"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000017" name="dei:EntityRegistrantName">Immunic, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 40%"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20250101__20251231_zXRSuPajrU7d"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 40%"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20250101__20251231_z7IscNOV7WWb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000019" name="dei:EntityTaxIdentificationNumber">56-2358443</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20250101__20251231_zJaLrNLzAnRh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000020" name="dei:EntityAddressAddressLine1">1200 Avenue of the Americas</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20250101__20251231_zlVv91EEpcz"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000021" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressCityOrTown_c20250101__20251231_zM45J2kHZfEi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000022" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>,&#160;<span id="xdx_900_edei--EntityAddressStateOrProvince_c20250101__20251231_z9WfvmJqnLC4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000023" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span></b></span></td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20250101__20251231_zQOJRHakcXfl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000024" name="dei:EntityAddressPostalZipCode">10036</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--CityAreaCode_c20250101__20251231_zCKbUxTzqJGl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000025" name="dei:CityAreaCode">(332)</ix:nonNumeric></span> <span id="xdx_909_edei--LocalPhoneNumber_c20250101__20251231_zPRY4kYPmtE3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000026" name="dei:LocalPhoneNumber">255-9818</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center; width: 30%"><span style="font-size: 10pt">Title of Each Class</span></td>
    <td style="font-size: 10pt; text-align: center; width: 25%"><span style="font-size: 10pt">Trading symbol(s)</span></td>
    <td style="font-size: 10pt; text-align: center; width: 45%"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20250101__20251231_zWtLbhy382Tk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000027" name="dei:Security12bTitle">Common Stock, $0.0001 par value</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20250101__20251231_zUV3QO07G3Rk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000028" name="dei:TradingSymbol">IMUX</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--SecurityExchangeName_c20250101__20251231_zaWVBCCzlUsh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(g) of the Act: None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the Registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_90E_edei--EntityWellKnownSeasonedIssuer_c20250101__20251231_zSbhoEdhWV0b"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000030" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the Registrant is not required to file
reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; <span id="xdx_906_edei--EntityVoluntaryFilers_c20250101__20251231_zBICa78bDNIe"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000031" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
<span id="xdx_905_edei--EntityCurrentReportingStatus_c20250101__20251231_z0bVIGEPJdx"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000032" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <span id="xdx_90F_edei--EntityInteractiveDataCurrent_c20250101__20251231_z0wa8cIvOkbj"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000033" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span>
No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of
&#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth
company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; width: 35%"><span style="font-size: 10pt">Large accelerated filer</span></td>
    <td style="font-size: 10pt; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font-size: 10pt; width: 35%"><span style="font-size: 10pt">Accelerated filer</span></td>
    <td style="font-size: 10pt; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20250101__20251231_zVRDDR3CKcW4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000034" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-size: 10pt">Smaller reporting company</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntitySmallBusiness_c20250101__20251231_zd3mnm3RCKBe"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000035" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-size: 10pt">Emerging growth company</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20250101__20251231_zRXXK1SI6j4l"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the Registrant has filed a report on
and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If securities are registered pursuant to Section 12(b) of the Act,
indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to
previously issued financial statements. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_edei--DocumentFinStmtErrorCorrectionFlag_c20250101__20251231_zH9hEKSdIzx4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000037" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether any of those error corrections are
restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive
officers during the relevant recovery period pursuant to &#167;240.10D-1(b)<span style="font-family: Times New Roman, Times, Serif">
&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> <span id="xdx_907_edei--EntityShellCompany_c20250101__20251231_zhUxuPw7JZRa"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityShellCompany">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate market value of the common equity held by non-affiliates
of the Registrant, based on the closing price of the common stock on The Nasdaq Stock Market on June 30, 2025 was $<span id="xdx_907_edei--EntityPublicFloat_iI_pdn6_c20250630_zGmgkVKJrTzk"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2025-06-30" id="Fact000039" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">83.1</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 16, 2026, <span id="xdx_90E_edei--EntityCommonStockSharesOutstanding_iI_c20260416_zqgSSdRtfwyj"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-04-16" id="Fact000040" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136,214,825</ix:nonFraction></span> shares of common stock, $0.0001 par
value, were outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Documents Incorporated by Reference: None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPLANATORY NOTE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Part III Information </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_901_edei--AmendmentDescription_c20250101__20251231_zBDztAuv3ZBi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000041" name="dei:AmendmentDescription">On February 26, 2026, Immunic, Inc., a Delaware Corporation (the &#8220;Company&#8221;)
filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the &#8220;Original Form 10-K&#8221;). The Original
Form 10-K omitted portions of Part III, Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation),
12 (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters), 13 (Certain Relationships and Related
Transactions, and Director Independence), and 14 (Principal Accountant Fees and Services) in reliance on General Instruction G(3) to Form
10-K, which provides that such information may be either incorporated by reference from the registrant&#8217;s definitive proxy statement
or included in an amendment to Form 10-K, in either case filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) not later
than 120 days after the end of the Company&#8217;s fiscal year.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We no longer expect that the definitive proxy statement for our 2026
annual meeting of stockholders will be filed within 120 days of December 31, 2025. Accordingly, this Amendment No. 1 to Form 10-K (this
&#8220;Amendment&#8221;) is being filed solely to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>amend and restate Part III, Items 10, 11, 12, 13, and 14 of the Original Form 10-K to include the information required by such Items;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>delete the reference on the cover of the Original Form 10-K to the incorporation by reference of portions of our proxy statement into
Part III of the Original Form 10-K; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>file a new certification of our principal executive officer, principal financial officer and principal accounting officer as an exhibit
to this Amendment under Item 15 of Part IV hereof, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (&#8220;Exchange
Act&#8221;). No financial statements are included in this Amendment and this Amendment does not contain or amend any disclosure with respect
to Items 307 and 308 of Regulation S-K; accordingly, paragraphs 3, 4 and 5 of the certifications have been omitted.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amendment does not otherwise change or update any of the disclosures
set forth in the Original Form 10-K, including the financial statements, and does not otherwise reflect any events occurring after the
filing of the Original Form 10-K. Accordingly, this Amendment should be read in conjunction with the Original Form 10-K and the Company&#8217;s
filings made with the SEC subsequent to the filing of the Original Form 10-K. Capitalized terms used herein and not otherwise defined
are defined as set forth in the Original Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As used in this report, the terms &#8220;Immunic, Inc.,&#8221; the
&#8220;Company,&#8221; &#8220;Immunic,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; mean Immunic, Inc. and its subsidiaries
unless the context indicates otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 14, 2026, the Company held a special meeting of stockholders
(the &#8220;Special Meeting&#8221;), during which the Company&#8217;s stockholders approved a proposal (the &#8220;Proposal&#8221;) to
amend the Company&#8217;s certificate of incorporation (the &#8220;Certificate of Incorporation&#8221;) to effect a reverse stock split
of the Company&#8217;s issued and outstanding common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), at a ratio of
not less than 1:10 (the &#8220;Reverse Stock Split&#8221;). The Company&#8217;s stockholders approved the Proposal at the Special Meeting,
and on April 22, 2026, following approval by resolution of the Company&#8217;s board of directors, the Company filed an amendment to the
Certificate of Incorporation to effect the Reverse Stock Split, at a ratio of 1-for-10 to be effective April 27, 2026. The information
in this Amendment does not give effect to the Reverse Stock Split unless specifically stated otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Immunic, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ANNUAL REPORT ON FORM 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Fiscal Year Ended December 31, 2025
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Table of Contents </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-size: 10pt"><span style="text-decoration: underline"></span><span style="font-size: 10pt"><b>PART
    III</b></span></td>
    <td style="font-size: 10pt; text-align: right">Page</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Item 10.</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><a href="#A-1">Directors, Executive Officers and Corporate Governance.</a></span></td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Item 11.</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><a href="#A-11">Executive Compensation.</a></span></td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">11</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Item 12.</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><a href="#A-24">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">24</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Item 13.</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><a href="#A-29">Certain Relationships and Related Transactions, and Director Independence.</a></span></td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">29</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Item 14.</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><a href="#A-30">Principal Accountant Fees and Services.</a></span></td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">30</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2" style="font-size: 10pt"><span style="font-size: 10pt">PART IV</span></td>
    <td style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Item 15.</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><a href="#A-31">Exhibits and Financial Statement Schedules.</a> <span style="color: blue"></span></span></td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">31</span></td></tr>
  <tr style="background-color: White">
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; font-size: 10pt"><span style="font-size: 10pt"><a href="#A-33">Signatures</a></span></td>
    <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">33</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="A-1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 10. Directors, Executive Officers and Corporate Governance.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition of the Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors is currently composed of nine members. Two of
our current directors, Dr. Vitt and Dr. Neermann, began their service in April 2019 in connection with the stock-for-stock exchange transaction
between the Company (then known as Vital Therapies, Inc.) and Immunic AG (the &#8220;Exchange Transaction&#8221;). Seven of the nine directors
that currently comprise our board are &#8220;independent directors&#8221; within the meaning of such term as set forth in the listing
standards of the Nasdaq Stock Market, LLC (&#8220;Nasdaq&#8221;). Our board is divided into three staggered classes of directors. At each
annual meeting of stockholders, a class of directors will be elected for a term of three years to succeed the class of directors whose
terms are then expiring.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the names, ages, and certain other information
for each director with a term expiring at the annual meeting (who is also a nominee for election as a director at the annual meeting)
and for each of the continuing members of our board. All information is as of April 21, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font-size: 10pt; width: 23%"><span style="font-size: 10pt">Name</span></td>
    <td style="border-bottom: black 1pt solid; font-size: 10pt; width: 10%"><span style="font-size: 10pt">Class</span></td>
    <td style="border-bottom: black 1pt solid; font-size: 10pt; width: 10%"><span style="font-size: 10pt">Age</span></td>
    <td style="border-bottom: black 1pt solid; font-size: 10pt"><span style="font-size: 10pt">Position</span></td>
    <td style="border-bottom: black 1pt solid; font-size: 10pt; width: 13%"><span style="font-size: 10pt">Director <br/>
Since</span></td>
    <td style="border-bottom: black 1pt solid; font-size: 10pt; width: 13%"><span style="font-size: 10pt">Current <br/>
Term <br/>
Expires</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Dr. Daniel Vitt</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">I</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">57</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Director, Chief Executive Officer</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2019</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2027</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Dr. Duane Nash</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">I</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">55</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Director </span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2019</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2027</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Ms. Simona Skerjanec</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">I</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">61</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Chair of the Board </span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2024</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2027</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Dr. Richard Rudick</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">III</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">75</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Director</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2023</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2026</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Thorvald Nagel </span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">III</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">31</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Director</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2026</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2026</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Dr. J&#246;rg Neermann</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">II</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">59</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Director</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2019</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2028</span></td></tr>
  <tr style="vertical-align: top; background-color: transparent">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Ms. Tamar Howson</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">II</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">77</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Director</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2019</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2028</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Mr. Barclay Phillips</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">II</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">63</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Lead Independent Director</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2019</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2028</span></td></tr>
  <tr style="vertical-align: top; background-color: transparent">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Mr. Jon Congleton&#160;&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">II</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">62</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Director</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2026</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">2028</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dr. J&#246;rg Neermann</b>. Dr. Neermann has been a member of the
Board since April 2019. Since 2023, Dr. Neermann has been a venture partner with Vorwerk Ventures, a private venture capital fund. He
most recently served as the CEO of the privately held German biotech company, Curexsys GmbH from May 2021 until September 2022. Prior
to this until the end of 2020, Dr. Neermann worked for Life Sciences Partners (&#8220;LSP&#8221;) and was the managing director of LSP
Services Deutschland GmbH, which provides management services for LSP V Co&#246;peratieve U.A., one of the Company&#8217;s stockholders.
He joined LSP in January 2007 and left the company in early 2021. Dr. Neermann&#8217;s prime focus and responsibility within LSP was to
invest in unlisted securities. Prior to joining LSP, Dr. Neermann was the managing director of Deutsche Venture Capital, a venture capital
and private equity division of Deutsche Bank, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures
in Germany where he also invested in the healthcare sector. Dr. Neermann has a strong scientific background and hands-on finance and investment
expertise and has served on the boards of numerous European biotech and life science companies. From September 2011 until June 2023, Dr.
Neermann served as a non-executive director at Vivoryon N.V., a German biotech company that went public on Euronext Amsterdam in 2014,
which is active in the development of novel, disease-modifying therapeutics against Alzheimer&#8217;s disease. Currently, Dr. Neermann
serves as a non-executive director at Idea AG, a private German company. Dr. Neermann was previously a supervisory board member of ViCentra
B.V., a Dutch limited liability company, and Eyesense GmbH, a German limited liability company, until January 2021, Ventaleon GmbH, a
German limited liability company, until December 2020, and Kuros AG, a Swiss-headquartered company, until May 2017. Dr. Neermann was also
a board member of Imcyse S.A., a Belgian limited liability company, until January 2021. Currently, he is owner and managing director of
Betula29 GmbH, a German limited liability company. Dr. Neermann studied biotechnology at the Technical University of Brunswick, Germany,
and MIT in Cambridge, USA, and holds a Master&#8217;s degree and a Ph.D. in biotechnology from the Technical University in Brunswick,
Germany. He also studied economics at the Technical University in Brunswick, Germany, and Harvard Business School. We believe that Dr.
Neermann is qualified to serve on our board due to his scientific background and extensive experience as an investor in the biotechnology
and healthcare industries, which enable him to contribute important insights to our board on strategic leadership and drug commercialization
matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.2pt 0pt 0"><b>Tamar Howson</b>. Ms. Howson has been a member of the
Board since October 2019. Ms. Howson has served as an independent director at MEI Pharma, Inc. since September 2019, and Cue Biopharma,
Inc. since September 2020. She previously served as an independent director at Organovo Holdings, Inc. from June 2013 until September
2019, Enzymotec until December 2017, ContraVir until October 2018 and Scientus Pharma until December 2019. From January 2009 until December
2011, Ms. Howson worked as a Senior Advisor on the transaction team at JSB-Partners, providing business development support to life sciences
companies. Before that, she served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals, Inc. Prior
to her role at Lexicon Pharmaceuticals, Inc, Ms. Howson was Senior Vice President, Corporate and Business Development at Bristol-Myers
Squibb Company, responsible for worldwide oversight and management of the identification, evaluation and negotiation of mergers and acquisitions,
licensing and other external alliance activities. Additionally, Ms. Howson spent nearly a decade at SmithKline Beecham, where she served
as Senior Vice President and Director, Business Development and managed the company&#8217;s USD 100 million venture capital fund, SR One.
We believe that Ms. Howson&#8217;s extensive experience in corporate and business development in the biotechnology and pharmaceutical
industries qualify her to serve as a member of our board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Barclay Phillips</b>. Mr. Phillips has been a member of the Board
since November 2019. From August 2020 to October 2024, Mr. Phillips was Chief Operating Officer and Chief Financial Officer of Ribometrix,
Inc., a discovery stage biotechnology company developing RNA-targeted small molecule therapeutics. Since September 2019, Mr. Phillips
has been the managing member of Domantle Consulting LLC, a business strategy consulting firm for biotechnology companies. From 2008 to
May 2019, Mr. Phillips served as the Chief Financial Officer for three separate Nasdaq listed, development stage biotechnology companies;
G1 Therapeutics, Inc. (GTHX), Novavax (NVAX) and Micromet (acquired by Amgen in 2012 for $1.2B). In addition to carrying the CFO role,
Mr. Phillips also held the title of SVP Corporate Development at G1 Therapeutics. During his tenure as CFO, Mr. Phillips was responsible
for all finance and accounting functions, financing strategy (successfully raising over $1.4B), Wall Street and investor relations, public
relations and corporate strategy and corporate development. Prior to his CFO experience, Mr. Phillips had extensive experience in life
science venture investing and public market investing, serving for 9 years as the Managing Director of Vector Fund Management, a late-stage
life sciences venture capital fund with over $250 million in committed capital and approximately 30 venture investments in biotechnology,
medical technology and healthcare services companies. In addition, Mr. Phillips was Biotechnology Analyst and Director of Venture Investments
for INVESCO Funds group, a no-load mutual fund family with a healthcare sector fund franchise totaling over $3.5 billion in assets under
management. Mr. Phillips has served on the boards of several public and private companies, including roles as Audit Chair and Chair of
the Nominating and Corporate Governance committees. He received a Bachelor of Arts degree in economics from the University of Colorado
at Boulder. We believe that Mr. Phillips&#8217; significant expertise in the areas of financing strategy, capital markets, and business
development for multiple, Nasdaq-listed life science companies qualify him to serve as a member of our board and lead independent director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dr. Daniel Vitt</b>. Dr. Vitt is our Chief Executive Officer and
a member of the board, positions he has held since April 2019. From January 2017 to 2022, he was also managing director of Immunic Research
GmbH in Halle (Saale), our Germany subsidiary. He joined Immunic in January 2017 from 4SC AG, a publicly listed stock company based in
Martinsried, Germany, which he co-founded in 1997. At 4SC, he served as Chief Scientific Officer and Chief Development Officer. In addition,
from December 2011 to November 2017, Dr. Vitt served as managing director of 4SC Discovery GmbH, a German limited liability company. As
a member of the executive board of 4SC, he was responsible for all research and development activities at 4SC group including four clinical
stage products. Dr. Vitt currently serves as managing director for Listrax UG, a German limited liability company, and Brauhaus Germering
GmbH, a German limited liability company. He is also a director of Immunic Australia Pty Ltd., an Australian limited liability company.
Dr. Vitt studied chemistry in Siegen and W&#252;rzburg, Germany from 1989 to 1994 and graduated from the University of W&#252;rzburg.
During his doctoral studies, he focused on the molecular design of small molecule therapeutics. In 1998, he received his Ph.D. from the
Institute of Organic Chemistry at the University of W&#252;rzburg. We believe that Dr. Vitt&#8217;s extensive senior management experience
in the life sciences industry, including as the Company&#8217;s Chief Executive Officer, qualify him to serve as a member of our board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dr. Duane Nash</b>. Dr. Nash has been a member of the Board since
January 2019 and served as Chairman of the Board of Directors from April 2019 to April 2020, and as Executive Chairman from April 2020
to February 2026. Dr. Nash joined the Company in 2012, prior to the Exchange Transaction and has held various leadership roles in the
Company, including Medical Director, Executive Vice President, Chief Business Officer, President, and Chief Executive Officer, a position
he held until April 2019. Prior to joining the Company, Dr. Nash held various positions at Wedbush PacGrow Life Sciences, an investment
bank, where he was employed from March 2009 to March 2012, serving most recently as Senior Vice President in Equity Research. Before that,
he was a research analyst at Pacific Growth Equities, an investment bank, from April 2008 through March 2009, which was subsequently acquired
by Wedbush Securities, Inc. Dr. Nash also practiced as an attorney from November 2002 to February 2008, most recently at the law firm
of Davis Polk &amp; Wardwell, where he focused on intellectual property litigation and corporate matters. Dr. Nash has served on the board
of directors of public and private companies in the pharmaceutical space since 2012. Dr. Nash earned a B.A. in biology from Williams College,
an M.D. from Dartmouth Medical School, a J.D. from the University of California, Berkeley, and an M.B.A. from the University of Oxford.
Dr. Nash completed his internship in general surgery at the University of California at San Francisco. We believe that Dr. Nash&#8217;s
expertise and experience as a director and his service in various executive capacities for the Company, along with his extensive experience
as an executive, research analyst and attorney, qualify him to serve as a member of our board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dr. Richard Rudick. </b>Dr. Rudick joined the Board in April 2023.
Dr. Rudick has served since January 2023 as the President and CEO of Astoria Biologica, a private biotechnology company developing novel
therapies for multiple sclerosis. Previously, Dr. Rudick served as the Vice President of Development Science at Biogen, Inc., a biotechnology
company which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, from May 2014
until September 2020. Dr. Rudick also served as a staff neurologist and director of the Mellen Center for the Cleveland Clinic from January
1987 until May 2014. Dr. Rudick holds an M.D. from Case Western Reserve University School of Medicine. We believe that Dr. Rudick&#8216;s
extensive leadership in clinical research and development experience of multiple sclerosis treatments qualify him to serve on our board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Ms. Simona Skerjanec.</b> Ms. Skerjanec joined the Board in July
2024. Ms. Skerjanec has nearly thirty years of global experience in the pharmaceutical industry overseeing product commercialization and
business strategy initiatives. From March 2015 until December 2023, Ms. Skerjanec held several leadership positions at Roche in Switzerland,
where she most recently served as Senior Vice President, Global Head of Neuroscience and Rare Diseases. In this role, Ms. Skerjanec led
business and global corporate strategy for Roche&#8217;s portfolio of neurological and rare diseases. Previously, Ms. Skerjanec served
as General Manager of Roche in Portugal and served as the Neuroimmunology Franchise Head where she was in charge of certain drug commercialization
efforts on behalf of the company. Prior to joining Roche, Ms. Skerjanec was Senior Vice President and Cardiovascular Franchise Head at
The Medicines Company where she held various roles in development and commercialization from July 2003 to February 2015. Before her employment
at The Medicines Company, Ms. Skerjanec held positions at Eli Lilly, Pfizer, and Johnson &amp; Johnson. Since May 2024, Ms. Skerjanec
has served on the board of directors of Avidity Biosciences. Ms. Skerjanec received her M.Pharm from the University of Ljubljana School
of Pharmacy and her MBA from Fairleigh Dickinson University. We believe that Ms. Skerjanec&#8217;s expertise and decades-long management
of research and development and product commercialization efforts in the therapeutic areas of rare diseases, cardiology and neurology
qualify her to serve on the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Mr. Thorvald Nagel. </b>Thorvald &#8220;Thor&#8221; Nagel joined
the Board in February 2026. Mr. Nagel has served as an Analyst at BVF, since July 2023, where he conducts in-depth equity research and
contributes to investment analysis across the life sciences sector. From June 2021 through July 2023, Mr. Nagel was a senior analyst at
Monashee Investment Management LLC. He previously held roles with Stifel Financial Corp. Mr. Nagel received his Master of Science from
the University of Notre Dame and his Bachelor&#8217;s degree in Chemical Engineering from Vanderbilt University. We believe that Mr. Nagel&#8217;s
expertise in the areas of financing strategy, capital markets, and business development for life science companies qualify him to serve
as a member of our board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Mr. Jon Congleton. </b>Mr. Congleton joined the Board in April 2026.
Mr. Congleton has served as President and Chief Executive Officer and as a member of the board of directors of Mineralys Therapeutics,
Inc. (&#8220;Mineralys&#8221;) since November 2020. Prior to joining Mineralys, Mr. Congleton was the Chief Executive Officer of Impel
NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis
Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries Ltd. (Teva), where
for over 18 years, he held positions in general management and global strategic marketing, including Senior Vice President of Teva&#8217;s
Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November
2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten
years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State
University. We believe that Mr. Congleton&#8217;s extensive senior management experience in the life sciences industry, including as the
President and Chief Executive Officer of Mineralys, qualify him to serve as a member of our board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The listing rules of Nasdaq require us to maintain a board comprised
of a majority of independent directors, as determined affirmatively by our board. In addition, the Nasdaq listing rules require that,
subject to specified exceptions, each member of our audit, compensation and nominating and governance committees must be independent.
Audit committee members and compensation committee members must also satisfy the independence criteria set forth in Rule 10A-3 and Rule
10C-1, respectively, under the Exchange Act. Under the Nasdaq listing rules, a director will only qualify as an &#8220;independent director&#8221;
if, in the opinion of our board, the director does not have a relationship that would interfere with the exercise of independent judgment
in carrying out his or her responsibilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board has undertaken a review of the independence of our directors
and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent
judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning his
or her background, employment and affiliations, including family relationships, our board has determined that none of Ms. Howson, Dr.
Neermann, Mr. Phillips, Dr. Rudick, Ms. Skerjanec, Mr. Congleton, and Mr. Nagel, representing seven of our nine directors, has a relationship
that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each is an
&#8220;independent director&#8221; as that term is defined under the Nasdaq listing rules. Dr. Nash and Dr. Vitt are not currently considered
independent directors because of their positions as former Executive Chairman and Chief Executive Officer, respectively. Mr. Phillips
is our lead independent director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In making these determinations, our board considered the relationships
that each non-employee director has with us and all other facts and circumstances our board deemed relevant in determining their independence,
including consulting relationships, family relationships and the beneficial ownership of our capital stock by each non-employee director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board Leadership Structure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board is currently chaired by Ms. Skerjanec. Our board believes
that the Company and its stockholders are currently best served by this leadership structure. As Chair of the Board, Ms. Skerjanec promotes
unified leadership and direction for our board and management and provides the critical leadership necessary for carrying out our strategic
initiatives. Ms. Skerjanec, together with our board&#8217;s strong committee system and independent directors, allows our board to maintain
effective oversight of our business operations, including independent oversight of our financial statements, executive compensation, selection
of director candidates, and corporate governance programs. We believe our current board leadership structure enhances the board&#8217;s
ability to effectively carry out its roles and responsibilities on behalf of our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, Mr. Phillips serves as our lead independent director.
As the lead independent director, Mr. Phillips is responsible for:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0%">&#160;</td>
    <td style="font-size: 10pt; width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">presiding at all meetings of the Board at which the Chairperson is not present, including any executive sessions of the independent Directors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0%">&#160;</td>
    <td style="font-size: 10pt; width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">calling meetings of the independent Directors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">serving as an advisor to the CEO and the Chairperson, as well as a non-exclusive liaison between the Chairperson and the independent Directors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">proposing items to the Chairperson and CEO for inclusion in agendas for meetings of the Board when the Lead Independent Director determines it is appropriate or necessary;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">being available, when appropriate, for consultation and direct communication with stockholders; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">fulfilling such other responsibilities and carrying out such special projects as the Board may from time to time request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Role of Board in Risk Oversight Process</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board has an active role, as a whole and also at the committee
level, in overseeing risk management. Our board is responsible for general oversight and regular review of risk management, including
financial, strategic, and operational risks. The compensation committee is responsible for overseeing the management of risks relating
to our executive compensation plans and arrangements, and whether our compensation policies and programs have the potential to encourage
excessive risk taking. The audit committee is responsible for overseeing the management of risks relating to accounting matters and financial
reporting. The nominating and governance committee is responsible for overseeing our corporate governance practices and the management
of risks associated with board independence and potential conflicts of interest. Although each committee is responsible for evaluating
and overseeing the management of certain risks, the entire board is regularly informed through discussions from committee members about
such risks. The board believes its leadership structure is consistent with and supports the administration of its risk oversight function.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board Meetings and Committees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During our fiscal year ended December 31, 2025, our board held 13 meetings
(including regularly scheduled and special meetings), and each director attended at least 75% of the aggregate of (i) the total number
of meetings of our board held during the period for which he or she has been a director and (ii) the total number of meetings held by
all committees of our board on which he or she served during the periods that he or she served.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board has established an audit committee, a compensation committee,
and a nominating and governance committee. The composition and responsibilities of each of the committees of our board are described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee members currently consist of Mr. Phillips, Dr.
Neermann, and Ms. Skerjanec. Mr. Phillips serves as the chairman. Each of the members of our audit committee is an independent director
under the Nasdaq listing rules, satisfies the additional independence criteria for audit committee members and satisfies the requirements
for financial literacy under the Nasdaq listing rules and Rule 10A-3 of the Exchange Act, as applicable. Our board has also determined
that Mr. Phillips qualifies as an audit committee financial expert within the meaning of the applicable rules and regulations of the SEC
and satisfies the financial sophistication requirements of the Nasdaq listing rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee oversees our corporate accounting and financial
reporting processes and the audit and review of our financial statements and assists our board in monitoring our financial systems and
financial compliance. Among other responsibilities, our audit committee also:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">has the sole authority to engage, appoint and oversee the work of our independent auditors; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">approves the hiring, discharging and compensation of our independent auditors as well as the compensation of any other accountants or auditors engaged by us in connection with the preparation of financial statements; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">pre-approve all auditing services and related terms and non-audit services to be provided to us by our independent auditors and any other accountants or auditors engaged by us in connection with the preparation of financial statements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">evaluates, at least annually, the qualifications, independence and performance of the independent auditors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">reviews our financial statements and our critical accounting policies and estimates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">assists our board in monitoring and reviewing the adequacy and effectiveness of our internal accounting and financial controls as well as our internal control policies and procedures on a regular basis; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">reviews our policies with respect to financial risk assessment and financial risk management; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">reviews and monitors our policies and procedures relating to related person transactions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">reviews, in consultation with our independent auditors, our annual audit plan and scope of audit activities, monitoring such annual audit plan&#8217;s progress and reviewing and approving the scope and staffing of such plan; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">discusses and, as appropriate, reviews with management and our independent auditors our annual and quarterly financial statements and annual and quarterly reports on Forms 10-K and 10-Q, among other matters.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee operates under a written charter approved by our
board and that satisfies the applicable rules and regulations of the SEC and the listing requirements of Nasdaq. The charter is available
on the corporate governance section of our website, which is located at http://ir.imux.com. Our audit committee held four meetings during
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Compensation Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The members of our compensation committee are Ms. Howson, Ms. Skerjanec,
Dr. Rudick, and Mr. Congleton. Mr. Congleton is currently the chair of our compensation committee. Our board has determined that each
member of our compensation committee is an independent director under the current rules of Nasdaq, satisfies the additional independence
criteria for compensation committee members under Rule 10C-1 and the Nasdaq listing rules, is a &#8220;non-employee director&#8221; within
the meaning of Rule 16b-3 under the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee oversees our corporate compensation programs.
The compensation committee also:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">assists our board in providing oversight of our compensation policies, plans and benefits programs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">reviews and recommends for board approval corporate goals and objectives relevant to the compensation of our Chief Executive Officer, our Section 16 executive officers and all other direct reports to the Chief Executive Officer who have material responsibilities within the Company (collectively referred to as the &#8220;Designated Employees&#8221;); </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">evaluates the performance of our Chief Executive Officer and Designated Employees in light of established goals and objectives; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">recommends compensation of our Chief Executive Officer and Designated Employees based on its evaluations; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">reviews and makes recommendations to our board with respect to the salary, benefit plans, compensation policies and programs for the Chief Executive Officer and Designated Employees;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">reviews and discusses with management the compensation disclosures required by SEC rules; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">engages a compensation consultant, legal counsel or other external advisors to advise on executive compensation and assess the independence of executive officers in accordance with Nasdaq listing rules; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">evaluates whether any compensation consultant, legal counsel or other external advisor has a conflict of interest in accordance with the SEC rules; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">prepares the annual compensation committee report required by SEC rules.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee operates under a written charter approved
by our board which satisfies the applicable rules and regulations of the SEC and the listing requirements of Nasdaq. The charter is available
on our website at http://ir.imux.com. Our compensation committee held five meetings during 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Nominating and Governance Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The members of our nominating and governance committee are Dr. Neermann,
Mr. Phillips and Dr. Rudick. Dr. Neermann is the chairman of our nominating and governance committee. Our board has determined that each
member of our nominating and governance committee is independent under the Nasdaq listing rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our nominating and governance committee oversees and assists our board
in reviewing and recommending nominees for election as directors. Among other responsibilities, the nominating and governance committee
also:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">evaluates and makes recommendations regarding the organization and governance of our board and its committees; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">assesses the performance of members of our board and makes recommendations regarding committee and chair assignments; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">recommends desired qualifications for board membership and conducts searches for potential members of our board;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">fulfills our board&#8217;s oversight responsibility with respect to our cybersecurity policies, overseeing our risk management with respect to cybersecurity, reviewing our adoption and implementation of systems, controls and procedures designed to prevent, detect and respond to cyber-attacks or security breaches involving us, and reviewing our cybersecurity insurance requirements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">periodically reviews our policy with respect to the United States Foreign Corrupt Practices Act;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">monitors the compliance of our senior officers with our Code of Business Conduct and Ethics; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">reviews and makes recommendations with regard to our corporate governance guidelines.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our nominating and governance committee operates under a written charter
approved by our board which satisfies the applicable rules and regulations of the SEC and the listing requirements of Nasdaq. The charter
is available on our website at http://ir.imux.com. Our nominating and governance committee held two meetings during 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Compensation Committee Interlocks and Insider Participation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None of the current or past members of our compensation committee is
or has been an officer or employee of the Company. None of our executive officers currently serves, or in the past year has served, as
a member of the compensation committee (or other board committee performing equivalent functions or, in the absence of any such committee,
the entire board) or director of any entity that has one or more executive officers serving on our compensation committee or our board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Considerations in Evaluating Director Nominees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In its evaluation of director candidates, including the member or members
of the board eligible for reelection, our nominating and governance committee will consider the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">The current size and composition of our board and the needs of the board and its respective committees; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">Factors such as character, integrity, judgment, diversity of experience, independence, area of expertise, corporate experience, length of service, potential conflicts of interest, other commitments, and the like. Our nominating and governance committee evaluates these factors, among others, and does not assign any particular weighting or priority to any of these factors; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">Other factors that our nominating and governance committee may consider appropriate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The nominating and governance committee also focuses on issues of diversity,
such as diversity in experience, international perspective, background, expertise, skills, age, gender, and ethnicity. The nominating
and governance committee does not have a formal policy with respect to diversity; however, our board and the nominating and governance
committee believe that it is essential that members of our board represent diverse viewpoints. Any nominee for a position on the board
must satisfy the following minimum qualifications:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">The highest levels of personal and professional ethics and integrity; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">Proven achievement and competence in the nominee&#8217;s field and the ability to exercise sound business judgment; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">Skills that are complementary to those of the existing board; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">The ability to assist and support management and make significant contributions to the Company&#8217;s success; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">An understanding of the fiduciary responsibilities required of a member of the board and the commitment of time and energy necessary to diligently carry out those responsibilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If our nominating and governance committee determines that an additional
or replacement director is required, the committee may take such measures as it considers appropriate in connection with its evaluation
of a director candidate, including candidate interviews, inquiry of the person or persons making the recommendation or nomination, engagement
of an outside search firm to gather additional information, or reliance on the knowledge of the members of the committee, board or management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After completing its review and evaluation of director candidates,
our nominating and governance committee recommends to our full board the director nominee. Our nominating and governance committee has
discretion to decide which individuals to recommend for nomination as directors and our board has the final authority in determining the
selection of director candidates for nomination to our board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Requirements for Stockholder Recommendations of a Candidate to our
Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is the policy of our nominating and governance committee to consider
recommendations for candidates to our board from our stockholders. A stockholder that wishes to recommend a candidate for consideration
by the committee as a potential candidate for director must direct the recommendation in writing to Immunic, Inc., 1200 Avenue of the
Americas, Suite 200, New York, New York 10036, Attention: Corporate Secretary, and must include the candidate&#8217;s name, home and business
contact information, detailed biographical data, relevant qualifications, a signed letter from the candidate confirming willingness to
serve, information regarding any relationships between us and the candidate and evidence of the recommending stockholder&#8217;s ownership
of our stock. Such recommendation must also include a statement from the recommending stockholder in support of the candidate, particularly
within the context of the criteria for board membership, including character, integrity, judgment, diversity of experience, independence,
area of expertise, corporate experience, potential conflicts of interest, other commitments and personal references.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our nominating and governance committee will consider the recommendation
but will not be obligated to take any further action with respect to the recommendation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Communications with the Board of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In cases where stockholders or other interested parties wish to communicate
directly with our non-management directors, messages can be sent to Immunic, Inc., Attention: Corporate Secretary, 1200 Avenue of the
Americas, Suite 200, New York, New York 10036. Our corporate secretary monitors these communications and will provide a summary of all
received messages to the board at each regularly scheduled meeting of the board. Our board generally meets on a quarterly basis. Where
the nature of a communication warrants, our corporate secretary may determine, in his or her judgment, to obtain the more immediate attention
of the appropriate committee of the board, non-management directors, independent advisors or our management, as our corporate secretary
considers appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.45pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.45pt"></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.45pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our corporate secretary may decide in the exercise of his or her judgment
whether a response to any stockholder or interested party communication is necessary. This procedure for stockholder and other interested
party communications with the non-management directors is administered by our nominating and governance committee. This procedure does
not apply to (i) communications to non-management directors from our officers or directors who are stockholders or (ii) stockholder proposals
submitted pursuant to Rule 14a-8 under the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Attendance at Annual Meetings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not have a formal policy regarding attendance by members of our
board at annual meetings of stockholders. We encourage, but do not require, directors to attend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Code of Business Conduct and Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board has adopted a written code of business conduct and ethics
that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal
accounting officer and controller, or persons performing similar functions. A copy of the code of business conduct and ethics is available
on the corporate governance section of our website, which is located at http://ir.imux.com. If we make any substantive amendments to,
or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment
or waiver on our website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Insider Trading Policy and Employee, Officer and Director Hedging</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board has adopted a written insider trading policy applicable to
all directors, officers and employees, which the Company believes is reasonably designed to promote compliance with insider trading laws,
rules and regulations, and applicable Nasdaq listing standards. Subject individuals are prohibited from engaging in transactions in publicly-traded
options, such as puts and calls, and other derivative securities with respect to the Company&#8217;s securities, including any hedging
or similar transaction designed to decrease the risks associated with holding Company securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Section 16(a) Beneficial Ownership Reporting Compliance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 16(a) of the Exchange Act requires our executive officers and
directors, and persons who own more than 10% of a registered class of our equity securities, to file reports of ownership and changes
of ownership on Forms 3, 4 and 5 with the SEC. Such directors, executive officers and 10% stockholders are required by SEC regulations
to furnish us with copies of all Section 16(a) forms they file.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based solely on our review of the copies of such forms we have received
and written representations from certain reporting persons that they filed all required reports, we believe that all of our officers,
directors and greater than 10% stockholders complied with all Section 16(a) filing requirements applicable to them with respect to transactions
during 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Compensation Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under our current outside director compensation policy, all non-employee
directors are entitled to receive the following cash compensation for their services:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">each non-employee director receives an annual base retainer of $45,000 except that the non-executive Chairman of the Board receives an additional annual base retainer of $35,000; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">in addition to the annual base retainer, the chair of our audit committee receives an annual fee of $20,000 and other members of our audit committee receive an annual fee of $10,000;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">in addition to the annual base retainer, the chair of our nominating and governance committee receives an annual fee of $10,000 and other members of our nominating and governance committee receive an annual fee of $5,000; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-size: 10pt">in addition to the annual base retainer, the chair of our compensation committee receives an annual fee of $15,000 and other members of our compensation committee receive an annual fee of $7,500.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All cash payments to non-employee directors are paid quarterly in arrears.
We also reimburse our directors for their reasonable expenses incurred in connection with attending board and committee meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The lead independent director is also entitled to receive an annual
cash retainer of $10,000 paid quarterly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Equity Compensation</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to cash compensation, our non-employee directors are also
entitled to equity awards under our outside director compensation policy. Each new non-employee director who first joins us is granted
an initial award of a non-statutory stock option to purchase 507,400 shares of Company common stock, which had increased from 100,000.
In addition, on the date of each annual meeting of stockholders, each non-employee director who has been a non-employee director for six
months or more on the date of the annual meeting is granted an annual award of a non-statutory stock option to purchase 253,700 shares
of Company common stock, which had increased from 50,000. The initial award vests in 36 monthly installments subject to the director&#8217;s
continued service with the Company. The annual award vests in 12 monthly installments subject to the director&#8217;s continued service
with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our compensation committee retained Aon to provide
recommendations on non-employee director compensation based on an analysis of market data compiled from comparable companies in the biotechnology
industry. The following table summarizes compensation paid to our non-employee directors during or with respect to the fiscal year ended
December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>Option </b></span>Awards ($)(1)</p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>All
Other Compensation</b></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Ms. Simona Skerjanec</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">52,160</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">96,975</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">149,135</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Mr. Jon Congleton<sup>(2)</sup>&#160;&#160;</b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Dr. Richard Rudick</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-size: 10pt"><b>Thorvald Nagel<sup>(3)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Dr. J&#246;rg Neermann</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">60,000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151,575</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Ms. Tamar Howson</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,840</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,815</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Mr. Barclay Phillips</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,975</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Ms. Maria Tornsen<sup>(4)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156,635</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Duane Nash was an executive officer of the Company during the year
ended December 31, 2025. For a description of his compensation see the section titled &#8220;Executive Compensation&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(1)</td><td>The amounts in the &#8220;Option Awards&#8221; column reflect the aggregate grant date fair value of stock options granted during
the calendar year computed in accordance with the provisions of Accounting Standards Codification (&#8220;ASC 718&#8221;) Compensation
&#8211; Stock Compensation. The assumptions that we used to calculate these amounts are discussed in Note 7 to our financial statements
appearing at the end of our Annual Report on Form 10-K for the year ended December 31, 2025. These amounts do not reflect the actual economic
value that will be realized by the director upon the vesting of the stock options, the exercise of the stock options, or the sale of the
common stock underlying such stock options.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(2)</td><td>Mr. Congleton joined the Board in April 2026, and so received no compensation during the year ended December 31, 2025.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(3)</td><td>Mr. Nagel joined the Board in February 2026, and so received no compensation during the year ended December 31, 2025.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(4)</td><td>Ms. Tornsen resigned from the Board in February 2026.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="A-11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 11. Executive Compensation.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For biographical information for Daniel Vitt, see &#8220;Composition
of the Board&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The names of our executive officers, their ages, their positions with
Immunic and other biographical information as of April 24, 2026, are set forth below. There are no family relationships among any of our
directors and executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 25%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 15%"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEDFF">
    <td><span style="font-size: 10pt">Dr. Daniel Vitt</span></td>
    <td><span style="font-size: 10pt">57</span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer, Director</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Jason Tardio</span></td>
    <td><span style="font-size: 10pt">49</span></td>
    <td><span style="font-size: 10pt">Chief Operating Officer, President</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEDFF">
    <td><span style="font-size: 10pt">Dr. Hella Kohlhof</span></td>
    <td><span style="font-size: 10pt">53</span></td>
    <td><span style="font-size: 10pt">Chief Scientific Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dr. Andreas Muehler</span></td>
    <td><span style="font-size: 10pt">62</span></td>
    <td><span style="font-size: 10pt">Chief Medical Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEDFF">
    <td><span style="font-size: 10pt">Inderpal Singh</span></td>
    <td><span style="font-size: 10pt">60</span></td>
    <td><span style="font-size: 10pt">General Counsel</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Patrick Walsh</span></td>
    <td><span style="font-size: 10pt">43</span></td>
    <td><span style="font-size: 10pt">Chief Business Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEDFF">
    <td><span style="font-size: 10pt">Glenn Whaley</span></td>
    <td><span style="font-size: 10pt">58</span></td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Werner Gladdines</span></td>
    <td><span style="font-size: 10pt">47</span></td>
    <td><span style="font-size: 10pt">Chief Development Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Jason Tardio</b>.&#160;Mr. Tardio joined Immunic in 2024 as our
President and Chief Operating Officer. From July 2021 to July 2024, Mr. Tardio was Chief Operating Officer of Ovid Therapeutics Inc. after
joining the firm as Chief Commercial Officer in November 2019. Prior to his role at Ovid Therapeutics, Inc., Mr. Tardio served as Vice
President, Head of the Multiple Sclerosis Franchise at Novartis AG from September 2018 to November 2019. Before his employment at Novartis,
Mr. Tardio worked for nine years in several capacities at Biogen Inc., where he most recently served as General Manager, Managing Director
for the firm&#8217;s Latin America South affiliate. Mr. Tardio commenced his career in the biopharmaceutical industry at Wyeth Pharmaceuticals
Inc. and Sepracor, Inc., respectively, in various sales, sales training, and marketing roles. Mr. Tardio holds a Bachelor of Science from
The College of New Jersey and an MBA in Pharmaceutical Marketing from St. Joseph&#8217;s University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dr. Hella Kohlhof</b>. Dr. Kohlhof joined Immunic in 2017 as our
Chief Scientific Officer. She studied biology in Aachen, Gothenborg (Sweden) and Munich and received her Doctorate in Biology from the
Ludwig Maximilians University of Munich (Germany). During her Ph.D. and post-doctoral position at the Institute of Clinical Molecular
Biology and Tumor Genetics at the Helmholtz Centre in Munich, she worked on the normal and malignant B cell development influenced by
Notch and Epstein Barr Virus mediated signaling. In 2008, she joined 4SC AG as a research scientist and group leader and established the
research laboratory for translational pharmacology. She worked on 4SC&#8217;s preclinical and clinical stage projects from the oncology
and immunology field, including IMU-838 and IMU-366. From 2011 onward, Dr. Kohlhof was responsible for the management and development
of 4SC&#8217;s epigenetic clinical stage small molecule inhibitor 4SC-202. In early 2015, as Director of Development Projects, she took
over responsibility for the complete development portfolio of 4SC AG. She currently serves as managing director of Immunic Research GmbH,
a German subsidiary of the Company, and Constanze Investment GmbH, a German limited liability company, respectively. Dr. Kohlhof has a
strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational
pharmacology, clinical trial design and bio-marker development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dr. Andreas Muehler</b>. Dr. Muehler joined Immunic in August 2016
as our Chief Medical Officer. Dr. Muehler received his medical degree (MD) from Humboldt-University in Berlin, Germany, and an MBA degree
from Duke University. After a short period in clinical work, Dr. Muehler has worked within the pharmaceutical industry since 1992, mostly
in the U.S., with leadership positions in preclinical and clinical development, business development and licensing and marketing. Since
2003, Dr. Muehler developed and managed multiple medical companies in the U.S. Among them were 3TP LLC d/b/a CAD Sciences (White Plains,
NY), a medical software company developing an imaging solution for early detection of breast and prostate cancer, and Cellectar Biosciences,
Inc. (Madison, WI), a biotech company developing new cancer therapeutics and cancer imaging agents. Dr. Muehler was also President and
CEO of MicroMRI Inc. (Langhorne, PA), a medical device company developing solutions for improved osteoporosis diagnosis and therapy monitoring
based on bone micro-architecture. He has been on the board of directors of multiple small medical technology companies. After moving to
Munich in 2009, Dr. Muehler became managing director of the small healthcare private equity fund Palladius Healthcare GmbH (Munich, Germany),
which acquired distressed medical technology companies. Thereafter, Dr. Muehler worked as interim manager and independent senior medical
consultant with multiple assignments for clients in the pharmaceutical and medical device industries. Dr. Muehler presently serves as
managing director of Xanomed GmbH, a German limited liability company, and is sole owner of Xanomed Holding USA, a Florida sole proprietorship.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Inderpal Singh</b>. Mr. Singh joined Immunic in June 2021 as our
General Counsel. He joined from Sandoz International GmbH, where he served as the Global Legal Head of Biopharma since January 2018. After
earning his college degree in India, Mr. Singh qualified as an attorney with specialization in Corporate and Commercial Law at Johannes-Gutenberg
University in Mainz, Germany. Mr. Singh completed two executive MBA programs at the University of Mannheim, Germany and INSEAD Business
School in Fontainebleau, France. During his tenure at Sandoz and as a member of various leadership teams, he was responsible for all legal
activities, including development, regulatory, and medical matters, as well as commercial operations, business development, alliance management
and market access for biopharma. Before that, from 2015 through 2017, Mr. Singh served at Merck KGaA as Global Legal Head of Global Manufacturing
and Supply and Regional Counsel of Middle East and Africa, Commonwealth of Independent States and Turkey. From 2013 to 2015, he was Legal
Director (Europe) at Biogen Idec International GmbH. Earlier in his career, Mr. Singh spent 15 years in legal positions of increasing
responsibility at Pfizer Deutschland GmbH and Pfizer Inc. (U.S.).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Patrick Walsh</b>. Mr. Walsh joined Immunic in October 2021 as our
Chief Business Officer. He joined from Akebia Therapeutics, Inc., where he served as Vice President of Business Development from July
2015 until October 2021 and completed an array of strategic transactions, including multiple partnerships, in-licenses, non-dilutive financings,
and a merger. Mr. Walsh holds both an M.S. in molecular, cellular and developmental biology and an MBA from the University of Michigan
and a B.A. in biology and economics from Colby College. Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which
time he worked on all aspects of business development. Earlier in his career, Mr. Walsh was a consultant to life science companies with
Capgemini SE and was on the healthcare investment banking team at Leerink Partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Glenn Whaley</b>. Mr. Whaley joined Immunic as Principal Accounting
Officer and Controller in December 2019. In April 2020, he was promoted to the position of Vice President Finance, Principal Financial
and Accounting Officer. In March 2022, he was promoted to the position of Chief Financial Officer. Mr. Whaley has more than 30 years of
experience in accounting and finance roles. Prior to joining us, Mr. Whaley was Vice President of Finance at Pernix Therapeutics, a branded
and generics pharmaceutical company, from March 2015 until May 2019. His responsibilities included Principal Financial and Accounting
Officer, from November 2018 until May 2019, Principal Accounting Officer and Controller from December 2017 until November 2018 and Vice
President of Financial Planning and Analysis from March 2015 until November 2017. Mr. Whaley was Vice President of Finance for Alvogen,
Inc., a global pharmaceutical company, from May 2011 until March 2015. His responsibilities included Vice President Finance of U.S. Operations
from August 2013 to March 2015 and Global Corporate Controller from May 2011 to August 2013. Prior to Alvogen, Mr. Whaley served as Corporate
Controller for ImClone Systems, a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology, from January
2007 to May 2011 and Senior Director of Financial Reporting from January 2005 to December 2006. Prior to ImClone Systems, Mr. Whaley served
in financial roles at increasing levels of responsibility in public accounting and the pharmaceutical and telecommunications industries.
Mr. Whaley holds a Bachelor of Science degree from Rutgers University Business School and is a Member of the New Jersey Society of Certified
Public Accountants and the American Institute of Certified Public Accountants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.05pt 0pt 8.45pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.05pt 0pt 8.45pt"></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.05pt 0pt 8.45pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Werner Gladdines</b>. Mr. Gladdines joined Immunic in January 2021
as Head of the IMU-838 Program, and since that time held positions of increasing responsibility with the Company, and was appointed Vice
President, Program Management &amp; Clinical Development Operations in February 2023. In July 2024, he was appointed Chief Development
Officer. Mr. Gladdines has more than 20 years of experience in building and leading global drug development, clinical operations and clinical
sciences teams in oncology, neurology and rare disease therapeutic areas across different commercial and clinical-stage biotechnology
companies, including AIMM Therapeutics B.V., Rainier Therapeutics, Inc., Biomarin Pharmaceutical Inc., Prosensa Therapeutics B.V., to-BBB
technologies B.V. and Genzyme Corp. During his career, Mr. Gladdines has also executed strategic development and operational plans that
have delivered timely and meaningful therapies for patients and has actively contributed to the registration of three medicinal products
and the successful delivery of over 20 international phase 1 to phase 4 clinical studies. Mr. Gladdines earned a master&#8217;s degree
in bio-pharmaceutical sciences from the University of Leiden, The Netherlands, where he focused on developing mathematical models describing
concentration-effect relationships of neuroactive steroids.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Processes and Procedures for Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee assists our board of directors in discharging
its responsibilities relating to oversight of the compensation of our chief executive officer and our other executive officers, including
reviewing and making recommendations to the board with respect to the compensation, plans, policies and programs for our chief executive
officer and our other executive officers and administering our equity compensation plans for our executive officers and employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee annually reviews the compensation, plans,
policies and programs for our chief executive officer and our other executive officers. In connection therewith, our compensation committee
considers, among other things, each executive officer&#8217;s performance in light of established individual and corporate goals and objectives
and the recommendations of our chief executive officer. In particular, our compensation committee considers the recommendations of our
chief executive officer when reviewing base salary and incentive performance compensation levels of our executive officers and when setting
specific individual and corporate performance targets under our annual executive incentive bonus plan for our executive officers. Our
chief executive officer has no input and is not present during voting or deliberations about his compensation. Our compensation committee
may delegate its authority to a subcommittee, but it may not delegate any power or authority required by agreement, law, regulation or
listing standard to be exercised by the compensation committee as a whole.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our nominating and governance committee has authority to review and
recommend to the board compensation programs for our outside directors, although this role has been predominantly undertaken by our compensation
committee, in consultation with members of our full board. Management generally does not have a role in the setting of director compensation.
Our nominating and governance committee may delegate its authority to a subcommittee, but it may not delegate any power or authority required
by agreement, law, regulation or listing standard to be exercised by the nominating and governance committee as a whole.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, our compensation committee has engaged Aon, an independent
compensation consulting firm, to evaluate our levels and types of executive and director compensation and to recommend changes as appropriate.
Among other objectives, Aon has assisted the compensation committee in identifying a peer group of companies based on our current stage
of development for the comparison of executive and director compensation and has also provided to the compensation committee comparative
data on executive and director compensation practices in our industry and general advice on our executive and director compensation programs.
The compensation committee consults regularly with Aon in connection with specific aspects of or questions relating to our executive and
director compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The compensation committee has the sole authority to approve the terms
of any engagement of Aon. Although our board of directors and compensation committee consider the advice and recommendations of our independent
compensation consultants as to our executive and director compensation programs, our board of directors and compensation committee ultimately
make their own decisions about these matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The compensation committee has a policy that requires any compensation
consultant retained by the committee to be independent of the Company and management. The compensation committee reviewed the independence
of Aon in light of this policy, SEC rules and Nasdaq listing standards regarding compensation consultants and concluded that Aon&#8217;s
work for the compensation committee does not raise any conflict of interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Clawback Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We adopted in 2023 a written compensation recovery policy in accordance
with applicable Nasdaq rules, a copy of which was filed as an exhibit to our Annual Report on Form 10-K filed with the SEC on February
22, 2024. The policy, which was effective as of October 2, 2023, generally provides that we will seek to recover incentive-based compensation
received by any current or former executive officer, without regard to any fault or misconduct of such executive officer, in the event
of an accounting restatement of the Company&#8217;s financial statements due to material noncompliance with any financial reporting requirement
under the securities laws during the three completed fiscal years immediately preceding the date we determine that an accounting restatement
is required. This policy supersedes the Compensation Recoupment Policy of the Company that was adopted and approved by the Board on July
2, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Compensation Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While we do not have a formal written policy in place with regard to
the timing of certain equity awards in relation to the disclosure of material nonpublic information, our Board and the Compensation Committee
do not seek to time equity grants to take advantage of information, either positive or negative, about our company that has not been publicly
disclosed. It has been our practice generally to grant initial equity awards to our officers and non-employee directors in connection
with their hiring or appointment to the Board, as applicable. We generally intend to issue equity awards to our officers. In addition,
non-employee directors receive grants of initial and annual equity awards, at the time of a director&#8217;s initial appointment or election
to the Board and at the time of each annual meeting of our stockholders, respectively, pursuant to our Non-Employee Director Compensation
Policy. Option grants generally are effective on the date the award determination is made by the Compensation Committee or the Board,
as the case may be, and the exercise price of options is typically based upon the Fair Market Value of our common stock as defined in
our 2019 Omnibus Equity Incentive Plan, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See also the full text of the Immunic, Inc. 2019 Omnibus Equity Incentive
Plan, as amended (the &#8220;Plan&#8221;), which is included as an exhibit to the Original Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.2pt 0pt 8.45pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the fiscal year ended December 31, 2025, we did not award any
equity awards to a named executive officer in the period beginning four business days before the filing of a periodic report on Form 10-Q
or Form 10-K, or the filing or furnishing of a current report on Form 8-K that discloses material nonpublic information, and ending one
business day after the filing or furnishing of such report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our named executive officers (&#8220;NEOs&#8221;) for the year ended
December 31, 2025 were Dr. Daniel Vitt, our Chief Executive Officer and Director; Dr. Duane Nash, our former Executive Chairman; Jason
Tardio, our Chief Operating Officer and President, Dr. Andreas Muehler, our Chief Medical Officer; and Glenn Whaley, our Chief Financial
Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: middle; font-weight: bold; text-align: left">Name and Principal Position</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="vertical-align: middle; font-weight: bold; text-align: left">Year</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Salary</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>($)(1)</b>&#160;</p></td><td>&#160;</td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Option</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Awards</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>($)<sup>(2)</sup></b></p></td><td>&#160;</td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Appreciation </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Rights</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>($)</b></p></td><td>&#160;</td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Awards</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>($)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td><td>&#160;</td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-Equity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Incentive Plan</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>($)</b></p></td><td>&#160;</td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>All Other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>($)</b></p></td><td>&#160;</td>
    <td colspan="3" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Total</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>($)</b></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 12%; text-align: left">Dr. Daniel Vitt</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">2025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">625,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,043,081</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">141,683</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">401,258</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">100,000</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">2,311,272</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-style: italic; text-align: left">Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">610,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,160,474</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">167,749</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,938,223</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Duane D. Nash(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">982,952</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Former Executive Chairman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388,416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,683</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,211,828</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Andreas Muehler</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">540,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,696</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,426</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,264,888</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Chief Medical Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">752,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,121</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,368,235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Glenn Whaley</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">463,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337,093</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">218,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,065,473</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637,957</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,171,957</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jason Tardio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">512,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,696</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,206,763</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">COO and President</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">670,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,030,219</td><td style="text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-size: 10pt">(1)</span></td>
    <td style="width: 0%">&#160;</td>
    <td><span style="font-size: 10pt">An exchange rate of 1.16569 Euro to US$ based on the average exchange rate for 2025 was used to convert payment amounts in euros for the table above for 2025. An exchange rate of 1.078 Euro to US$ based on the average exchange rate for 2024 was used to convert payment amounts in euros for the table above for 2024. Dr. Vitt received payment of his salary in US$ in 2025 and in Euros in 2024. Dr. Muehler received payment in both USD and Euros for all years presented.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-size: 10pt">(2)</span></td>
    <td style="width: 0%">&#160;</td>
    <td><span style="font-size: 10pt">The amounts in the &#8220;Option Awards&#8221; column reflect the aggregate grant date fair value of stock options granted during the calendar year computed in accordance with the provisions of ASC 718. The assumptions that we used to calculate these amounts are discussed in Note 7 to our financial statements appearing at the end of our Annual Report on Form 10-K for the year ended December 31, 2025. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-size: 10pt">(3)</span></td>
    <td style="width: 0%">&#160;</td>
    <td><span style="font-size: 10pt">Represents a housing allowance for Dr. Vitt while relocated in the United States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-size: 10pt">(4)</span></td>
    <td style="width: 0%">&#160;</td>
    <td><span style="font-size: 10pt">For 2025 and 2024, the amount in the &#8220;Salary&#8221; column represents combined compensation for service as Executive Chairman.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-size: 10pt">(5)</span></td>
    <td style="width: 0%">&#160;</td>
    <td><span style="font-size: 10pt">For Dr. Muehler, represents a pension allowance. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-Equity Incentive Plan Compensation and Bonus</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We offer our NEOs the opportunity to earn annual discretionary cash
bonuses, as determined by our board of directors or the compensation committee annually at their discretion. Actual bonus amounts for
our NEOs are determined by our compensation committee after consideration of Dr. Vitt&#8217;s recommendations (except with respect to
his individual bonus). Our CEO makes recommendations to the compensation committee regarding annual bonus payouts for the executive officers
other than himself and does not participate in any discussions with the compensation committee regarding his own compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For 2025, annual bonuses were based on such factors as the board of
directors and the compensation committee deemed appropriate, including a variety of individual and Company priorities and objectives relating
to 2025, as well as each individual NEO&#8217;s performance as it related to his area of responsibility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2026, the board approved a 115% bonus payout for 2025 to
each of Daniel Vitt, Andreas Muehler, Glenn Whaley and Jason Tardio. The bonuses were paid in March and April of 2026. In addition, a
payment of $162,000 was made to Duane Nash, former Executive Chairman of the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Agreements With Our Named Executive Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Dr. Daniel Vitt</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Prior Employment Agreement and Related Arrangements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with Dr. Vitt&#8217;s planned temporary relocation to
the United States, on December 13, 2024, Dr. Vitt and the Company entered into a new employment agreement (the &#8220;New Vitt Agreement&#8221;).
During the term of the New Vitt Agreement, Dr. Vitt&#8217;s services on the Management Board of Immunic AG will be paused. The New Vitt
Agreement provides for Dr. Vitt&#8217;s current annual salary of $610,000 and annual target bonus of 55% of Dr. Vitt&#8217;s annual salary.
From time to time, Dr. Vitt may continue to receive equity incentive awards pursuant to the Company&#8217;s 2019 Omnibus Equity Incentive
Plan (or supplemental or succeeding equity plan as applicable). Certain compensation received by Dr. Vitt, whether in concordance with
the New Vitt Agreement or otherwise, is subject to the Company&#8217;s clawback compensation policy. Under the New Vitt Agreement, Dr.
Vitt is entitled to participate in employee benefit plans of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, on a monthly basis and subject to certain conditions,
the Company may reimburse Dr. Vitt in respect of $100,000 of housing expenses in the United States during the term of the New Vitt Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 18, 2024, in view of Dr. Vitt&#8217;s planned temporary
relocation of employment to the United States as governed by the New Vitt Agreement, Dr. Vitt entered into a separate agreement with Immunic
AG in order to pause that certain service agreement by and between Immunic AG and Dr. Vitt, dated December 19, 2023 (the &#8220;Suspension
Agreement&#8221;). Under the terms of the Suspension Agreement, in general, Dr. Vitt will not receive remuneration relating to his service
on the Management Board of Immunic AG during the period of time of the suspension of his service relationship with the Management Board
(the &#8220;Service Agreement Suspension Period&#8221;). Dr. Vitt will be released from his duties as a member of the Management Board
during the Service Agreement Suspension Period. The Suspension Agreement provides for Dr. Vitt&#8217;s reappointment to the Management
Board following the completion of the Service Agreement Suspension Period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>New Employment Agreement </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 29, 2025, Dr. Daniel Vitt entered into an employment agreement
with the Company setting forth the terms and conditions regarding Dr. Vitt&#8217;s remuneration and other provisions of employment with
the Company while he is performing services in the United States (the &#8220;New Employment Agreement&#8221;). Pursuant to the New Employment
Agreement, Dr. Vitt has agreed to spend fifty percent (50%) of his working time in the United States during the term of the New Employment
Agreement and to spend the remaining fifty percent (50%) of his working time in Germany. While working in the United States, Dr. Vitt
will perform services only for the Company and while working in Germany, Dr. Vitt will perform services only as a member of the Management
Board (the &#8220;Management Board&#8221;) of Immunic AG, a wholly-owned subsidiary of the Company, pursuant to a management agreement
(the &#8220;Management Board Agreement&#8221;) between Dr. Vitt and Immunic AG.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The New Employment Agreement provides that Dr. Vitt will continue to
serve as Chief Executive Officer of the Company until the earlier of (i) the date that Dr. Vitt is reappointed on a full-time basis to
the Management Board of Immunic AG and (ii) Dr. Vitt&#8217;s Date of Termination (as defined in the New Employment Agreement). During
the Term of Employment (as defined in the New Employment Agreement), Dr. Vitt shall devote (i) fifty percent (50%) of his working time,
attention and effort to the affairs of the Company, excluding any periods of disability, vacation, or sick leave to which Dr. Vitt is
entitled, and shall use his reasonable best efforts to perform the duties properly assigned to him thereunder and to promote the interests
of the Company, and (ii) the remaining fifty percent (50%) of his working time to perform services for Immunic AG in Germany, pursuant
to the Management Board Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The New Employment Agreement provides, among other things, an annual
base salary of $305,000 and an annual target bonus of 55% of Dr. Vitt&#8217;s annual salary. From time to time, Dr. Vitt may continue
to receive equity incentive awards pursuant to the Company&#8217;s 2019 Omnibus Equity Incentive Plan (or supplemental or succeeding equity
plan as applicable). Certain compensation received by Dr. Vitt, whether in accordance with the New Employment Agreement or otherwise,
is subject to the Company&#8217;s clawback compensation policy (and any other similar policy as applicable).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the Management Board Agreement, Dr. Vitt is
entitled to participate in employee benefit plans of Immunic AG. Additionally, the Company may reimburse Dr. Vitt up to $50,000 for U.S.
housing expenses during the term of the New Employment Agreement, subject to the conditions set forth in the New Employment Agreement.
Dr. Vitt shall also be entitled to customary reimbursement for certain business- or employment-related expenses during the Term of Employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 29, 2025, Dr. Vitt entered into an addendum (the &#8220;Addendum&#8221;)
to that certain service agreement by and between Immunic AG and Dr. Vitt, as most recently amended on December 19, 2023 (the &#8220;Service
Agreement&#8221;), which agreement was suspended pursuant to the agreement on suspension of the service agreement (the &#8220;Suspension
Agreement&#8221;) by and between Immunic AG and Dr. Vitt, dated December 18, 2024. Pursuant to the Addendum, the suspension of the Service
Agreement under the Suspension Agreement shall be terminated without replacement effective December 31, 2025. Pursuant to the Addendum,
Dr. Vitt shall devote fifty percent (50%) of his working time to Immunic AG. Additionally, the Addendum provides for, among other things:
(i) a fixed annual salary of &#8364;282,826.50, payable on a monthly basis; (ii) annual variable remuneration of up to &#8364;155,786.50
if certain annual targets are achieved; and (iii) total annual vacation of 30 working days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Duane Nash</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Agreements with Immunic, Inc. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 17, 2020, the Company entered into an employment agreement
with Dr. Nash (the &#8220;Executive Chairman Agreement&#8221;). The Executive Chairman Agreement establishes an &#8220;at will&#8221;
employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020.
Pursuant to the Executive Chairman Agreement, Dr. Nash is entitled to receive: (i) a monthly base salary of $25,417 (it being agreed that
such fee shall be inclusive of any fees associated with Mr. Nash&#8217;s services as both a director of the Company and in the capacity
of Executive Chairman), (ii) employee benefits including, health insurance, dental insurance, basic life and accidental death and dismemberment
insurance, long and short term disability insurance and participation in the Company&#8217;s 401(k) Plan, and (iii) reimbursements for
pre-approved reasonable business- related expenses incurred in good faith in the performance of the Dr. Nash&#8217;s duties for the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 15, 2020, the Company and Dr. Nash entered into an addendum
to the Executive Chairman Agreement, pursuant to which the term of the agreement was extended to April 15, 2021. The Company agreed to
make a one-time award to Dr. Nash of 120,000 stock options, which vest in six monthly installments starting on November 15, 2020. On April
15, 2021, the Company and Dr. Nash entered into a second addendum to the Executive Chairman Agreement, pursuant to which the term of the
agreement was extended to April 15, 2022. In connection therewith, the Company made a one-time award of 90,000 stock options to Dr. Nash,
which began to vest monthly over a period of 12 months commencing on May 15, 2021, and increased Dr. Nash&#8217;s monthly base salary
to $27,960 from $25,417.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 15, 2022, the Company and Dr. Nash entered into a third addendum
to the Executive Chairman Agreement, pursuant to which the term of the agreement was extended to December 31, 2022. In connection therewith,
the Company made a one-time award of 75,000 stock options to Dr. Nash, which will vest monthly over a period of 12 months commencing on
April 10, 2022, and increased Dr. Nash&#8217;s monthly base salary to $29,358 from $27,960.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 28, 2022, the Company and Dr. Duane Nash entered into Addendum
Number 4 to the Executive Chairman Agreement dated April 17, 2020, to extend the term of Dr. Nash&#8217;s employment as Executive Chairman
of the Board of Directors of the Company to December 31, 2023. In connection with the addendum, the Company increased Dr. Nash&#8217;s
monthly base salary to $30,250 from $29,358. On October 17, 2023, the Company and Dr. Duane Nash entered into Addendum Number 5 to the
Executive Chairman Agreement to extend the term of Dr. Nash&#8217;s employment as Executive Chairman of the Board of Directors of the
Company to December 31, 2024. In connection with the addendum, the Company increased Dr. Nash&#8217;s monthly base salary to $32,368 from
$30,250. On August 29, 2024, the Company and Dr. Duane Nash entered into Addendum Number 6 to the Executive Chairman Agreement to extend
the term of Dr. Nash&#8217;s employment as Executive Chairman of the Board of Directors of the Company to December 31, 2025. In connection
with Addendum Number 6, the Company increased Dr. Nash&#8217;s monthly base salary in 2025 to $33,986 from $32,368 (which includes the
cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive
Chairman Agreement remain the same.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Agreements with Gliomic Therapeutics Inc.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 29, 2025, in connection with the Company&#8217;s incorporation
of Gliomic Therapeutics Inc., a Delaware corporation, and a wholly-owned subsidiary of the Company (&#8220;Gliomic&#8221;), Duane Nash,
entered into an employment agreement (as described in this section, the &#8220;Nash Agreement&#8221;) with the Company, pursuant to which
Dr. Nash would serve as Chief Executive Officer and President of Gliomic, effective January 1, 2026. The Nash Agreement provides for,
among other things: (i) a monthly base salary of $33,987; (ii) entitlement to participate in all Company employee benefit plans, programs
and arrangements made available generally to the Company&#8217;s senior executives or to other full-time employees; and (iii) customary
reimbursement for certain business- or employment-related expenses. Certain compensation received by Dr. Nash, whether in accordance with
the Nash Agreement or otherwise, is subject to the Company&#8217;s clawback compensation policy (and any other similar policy as applicable).
The Nash Agreement also provides that upon Dr. Nash&#8217;s termination of employment for any reason, Dr. Nash shall be entitled to (i)
a lump sum payment on the Date of Termination (as defined in the Nash Agreement) in an amount equal to the sum of Dr. Nash&#8217;s earned
but unpaid base salary through the Date of Termination; (ii) COBRA reimbursement for six months; and (iii) any other benefits or rights
Dr. Nash accrued or earned through the Date of Termination, in accordance with the terms of the applicable fringe or employee benefit
plans and programs of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Nash Agreement provides that Dr. Nash will continue to serve as
Chief Executive Officer and President of Gliomic until the Date of Termination. During the Term of Employment (as defined in the Nash
Agreement), the Company will not pay Dr. Nash any additional cash retainer for serving on the Board. Upon termination of the Nash Agreement,
Dr. Nash shall be entitled to be paid the cash retainer payable to outside directors on the Board of the Company and to the Chairman of
the Board of Company for the period of time beginning from and after the Date of Termination and for so long as Dr. Nash remains on the
Board and serves as the Chairman of the Board. On December 31, 2025, Dr. Nash&#8217;s employment agreement with the Company, pursuant
to which Dr. Nash was appointed Executive Chairman of the Company, expired by its terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Dr. Andreas Muehler</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Service Agreement with Immunic AG</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 4, 2019, Immunic AG entered into an addendum to the Service
Agreement (as amended, the &#8220;Muehler Service Agreement&#8221;), dated August 22, 2016, between Immunic AG and Dr. Andreas Muehler,
our Chief Medical Officer. The Muehler Service Agreement provided that Dr. Muehler would continue to serve on the management board of
Immunic AG until August 31, 2021, would receive an annual salary of EUR 154,000, to be paid in 12 monthly installments, and an annual
bonus of 30% of his annual base salary upon achievement of certain targets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 10, 2021, Dr. Muehler and Immunic AG entered into a second
addendum to the Muehler Service Agreement, pursuant to which Dr. Muehler&#8217;s annual salary was increased to EUR 177,100 and his annual
target bonus was increased to 35%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 10, 2022, Dr. Muehler and Immunic AG entered into a third
addendum to the Muehler Service Agreement. Pursuant to this third addendum, Dr. Muehler continued to serve on the management team of Immunic
AG until December 31, 2023, and received an annual salary of EUR 204,155, paid in 12 monthly installments, and a targeted yearly bonus
of up to EUR 81,662 upon achievement of certain targets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 16, 2023, Dr. Muehler and Immunic AG entered into a fourth
addendum to the Muehler Service Agreement. Pursuant to this fourth addendum, Dr. Muehler would continue to serve on the management team
of Immunic AG until December 31, 2023. Dr. Muehler would receive an annual salary of EUR 223,768, to be paid in 12 monthly installments,
and a targeted yearly bonus of up to EUR 89,507.20 upon achievement of certain targets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 18, 2023, Dr. Muehler and Immunic AG entered into a fifth
addendum to the Muehler Service Agreement, pursuant to which Dr. Muehler continued to serve on the management team of Immunic AG until
December 31, 2026. Dr. Muehler will receive an annual salary of EUR 231,825, to be paid in 12 monthly installments, and a targeted yearly
bonus of up to EUR 92,730 (40% of base salary) upon achievement of certain targets. In connection with the fifth addendum to the Muehler
Service Agreement, Dr. Muehler was granted accelerated vesting of stock options upon termination of employment under specified circumstances
and a one-year exercise period following termination, subject to specified conditions including providing post-employment assistance with
the transition of his duties to other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Employment Agreement with Immunic, Inc.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 4, 2019, Dr. Muehler also entered into a separate employment
agreement (the &#8220;Muehler Employment Agreement&#8221;) with the Company. The Muehler Employment Agreement provided that Dr. Muehler
would continue to serve as Chief Medical Officer until August 31, 2021, and would dedicate approximately 40% of his time to the affairs
of the Company and approximately 60% of his time to the affairs of Immunic AG. The Muehler Employment Agreement provided for an annual
salary of $180,000 and an annual bonus of at least 18% of his annual base salary upon achievement of certain targets. Dr. Muehler also
received an inaugural equity award of an option to purchase 40,000 shares of Company common stock. Dr. Muehler is also eligible for reimbursement
for certain expenses, and customary insurance and benefits programs of the Company. Effective September 1, 2020, Dr. Muehler&#8217;s annual
base salary was increased to $198,000. In June 2021 and effective September 1, 2021, Dr. Muehler&#8217;s annual base salary under the
Muehler Employment Agreement was increased to $227,000 and his yearly target bonus was increased to 35%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.2pt 0pt 8.45pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective January 10, 2022, Dr. Muehler&#8217;s base salary that is
paid by the Company was increased from $227,000 to $230,287, and his targeted yearly bonus was changed to up to $92,114.80 upon achievement
of certain targets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 19, 2023, Dr. Muehler also entered into a separate employment
agreement (&#8220;Second Muehler Employment Agreement&#8221;) with the Company. The Second Muehler Employment Agreement provides that
Dr. Muehler will continue to serve as Chief Medical Officer until December 31, 2026, and will dedicate approximately 50% of his time to
the affairs of the Company and approximately 50% of his time to the affairs of Immunic AG. This agreement provides for an annual salary
of $250,000 USD and an annual bonus of at least 40% of annual base salary upon achievement of certain targets. Dr. Muehler is also eligible
for reimbursement for certain expenses, and customary insurance and benefits programs of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If Dr. Muehler&#8217;s employment is terminated by the Company without
Cause or by him for Good Reason (each as defined in the Second Muehler Employment Agreement), he is entitled to (i) twelve months&#8217;
base salary, (ii) any accrued but unpaid annual bonus for the fiscal year ended prior to termination, and (iii) reimbursement of certain
COBRA premiums. Additionally, all of his outstanding equity awards will vest and become immediately exercisable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.2pt 0pt 8.45pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.2pt 0pt 8.45pt"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.2pt 0pt 8.45pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Glenn Whaley</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 21, 2019, the Company and Mr. Whaley entered into an offer letter (the &#8220;Offer Letter&#8221;). Pursuant to the Offer
Letter, Mr. Whaley initially served as Principal Accounting Officer and Controller, and he was promoted in April 2020 to Vice President
Finance, Principal Financial and Accounting Officer. The Offer Letter provided for an annual base salary of $295,000 and an annual bonus
of 30% of annual base salary upon achievement of certain targets. Effective September 1, 2020, Mr. Whaley's annual base salary was
increased to $320,000. On June 10, 2021, the Company and Mr. Whaley entered into an employment agreement (the "Whaley Employment
Agreement") which provided for an annual salary of $390,000, subject to periodic review and adjustments made by the Company, and
an annual bonus of at least 35% of annual base salary upon achievement of certain targets. On March 10, 2022, Mr. Whaley was promoted
to Chief Financial Officer. Effective January 1, 2024, Mr. Whaley's salary was increased to $445,000 and a yearly target bonus was
increased to 40%. Effective April 1, 2025, Mr. Whaley's salary was increased to $475,000. Mr. Whaley is also entitled to a severance
payment equivalent to twelve months of Mr. Whaley's yearly base salary if (i) Mr. Whaley were to be terminated without "cause"
(as such term is defined in the Whaley Employment Agreement), or (ii) the Company were to elect not to renew the term of Mr. Whaley&#8217;s
employment with the Company. Mr. Whaley is also eligible for reimbursement for certain expenses, and customary insurance and benefits
programs of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Jason Tardio</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 9, 2024, the Company and Mr. Tardio entered into an employment
agreement (the &#8220;Tardio Agreement&#8221;). Pursuant to the Tardio Agreement, Mr. Tardio will receive a yearly base salary of $500,000,
subject to periodic review and adjustments made by the Company and is eligible for a yearly bonus amount of up to 40% of the yearly base
salary upon achievement of certain individual and company goals. In addition, the Company paid Mr. Tardio a signing bonus in the amount
of $120,000, 50% payable in the first month and 50% payable after six months of employment. Mr. Tardio is also entitled to a severance
payment equivalent to twelve months of Mr. Tardio&#8217;s yearly base salary if (i) Mr. Tardio were to be terminated without &#8220;cause&#8221;
(as such term is defined in the Tardio Agreement), or (ii) the Company were to elect not to renew the term of Mr. Tardio&#8217;s employment
with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Potential Payments Upon Termination or Change in Control </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below reflects, as applicable, amounts payable to our current
named executive officers in connection with a termination by the Company without cause, by the executive for good reason, or upon non-renewal
by the Company in the event of a change in control. For purposes of our agreements with our named executive officers, &#8220;cause&#8221;
generally means, in the judgement of the Company, one or more of the following: (i) the executive&#8217;s willful failure to perform his
duties hereunder or the lawful directives of the Board or nominees thereof (other than as a result of illness or injury), (ii) the conviction
of, or plea of nolo contendere by, executive to, a felony or a crime involving moral turpitude, (iii) executive&#8217;s commission of
any willful acts of personal dishonesty in connection with his responsibilities as an employee of the Company that could reasonably be
expected to materially impair or damage the property, goodwill, reputation, business or finances of the Company, (iv) executive&#8217;s
willful and material violation of the Company&#8217;s policies regarding ethics or conduct (including sexual harassment and other similar
policies) that could reasonably be expected to impair or damage the property, goodwill, reputation, business or finances of the Company
or its affiliates or (v) executive&#8217;s breach of his obligations under the Confidentiality Agreement. For purposes of our agreements
with our named executive officers, &#8220;good reason&#8221; generally means, one or more of the following: (i) the assignment to executive
duties materially inconsistent with executive&#8217;s position, including any change in status, title, authority, duties or responsibilities
or any other action which results in a material diminution in such status, title, authority, duties or responsibilities; (ii) a material
reduction in the executive&#8217;s base salary by the Company or, if applicable (iii) the relocation of executive office.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of the potential payments that each of our current named
executive officers would have received upon the occurrence of these events, assuming that each triggering event occurred on December 31,
2025, is set forth below. &#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Triggering Event</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Cash Severance</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Accelerated equity awards (1)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Bonus (2)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Vacation days</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Continued Health (3)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">($)</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">($)</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">($)</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">($)</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">($)</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">($)</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Daniel Vitt</b></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-weight: bold; font-style: italic; text-align: left">Termination of Employment Without Cause/Resignation for Good Reason Apart from a Change in Control</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">634,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">4,429,347</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">348,920</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">73,154</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">42,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">5,527,821</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Termination of Employment Without Cause/Resignation for Good Reason in Connection with a Change in Control</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">951,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,429,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">348,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,154</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,866,021</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Duane Nash</b></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left">Termination of Employment Without Cause/Resignation for Good Reason Apart from a Change in Control</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left">Termination of Employment Without Cause/Resignation for Good Reason in Connection with a Change in Control</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Andreas Muehler</b></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Termination of Employment Without Cause/Resignation for Good Reason Apart from a Change in Control</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">548,421</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,649,122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,522,191</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Termination of Employment Without Cause/Resignation for Good Reason in Connection with a Change in Control</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">548,421</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,649,122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,522,191</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Glenn Whaley</b></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left">Termination of Employment Without Cause/Resignation for Good Reason Apart from a Change in Control</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">700,353</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,443,891</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left">Termination of Employment Without Cause/Resignation for Good Reason in Connection with a Change in Control</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,400,706</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,144,244</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Jason Tardio</b></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Termination of Employment Without Cause/Resignation for Good Reason Apart from a Change in Control</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">520,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">820,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,630,061</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Termination of Employment Without Cause/Resignation for Good Reason in Connection with a Change in Control</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">520,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,640,121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,450,121</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(1)</td><td>The amounts in the &#8220;Accelerated Equity Awards&#8221; column reflect the aggregate grant date fair value of stock options granted
during the calendar year computed in accordance with the provisions of ASC 718. The assumptions that we used to calculate these amounts
are discussed in Note 7 to our financial statements appearing at the end of our Annual Report on Form 10-K for the year ended December
31, 2025. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting
of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.Represents 100%
of the executives target bonus effect for the fiscal year in which the executive is terminated, prorated based on the actual amount of
time the executive is employed by the Company.&#160;</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>(2)</td><td>Represents 100% of the executives target bonus effect for the fiscal
year in which the executive is terminated, prorated based on the actual amount of time the executive is employed by the Company.</td></tr>
                                                              </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(3)</td><td>Continued health payment represents 12-months of COBRA coverage except for Daniel Vitt in a change in control scenario where he receives
18 months of COBRA coverage.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Outstanding Equity Awards as of December 31, 2025</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth certain information
concerning outstanding equity for our named executive officers as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="15" style="font-weight: bold; text-align: center"><span style="font-size: 7pt">OPTION AWARDS</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="15" style="font-weight: bold; text-align: center"><span style="font-size: 7pt">STOCK APPRECIATION RIGHTS AWARDS</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 7pt">Name</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-size: 7pt">GRANT DATE</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 7pt">NUMBER OF SECURITIES UNDERLYING UNEXERCISED
    OPTIONS EXERCISABLE</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>NUMBER OF SECURITIES UNDERLYING UNEXERCISED
    OPTIONS UNEXERCISABLE<sup>(1)</sup></b></span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 7pt">OPTION EXERCISE PRICE ($)</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-size: 7pt">OPTION EXPIRATION DATE</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-size: 7pt">GRANT DATE</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 7pt">NUMBER OF SECURITIES UNDERLYING UNEXERCISED
    OPTIONS EXERCISABLE</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 7pt">NUMBER OF SECURITIES UNDERLYING UNEXERCISED
    OPTIONS UNEXERCISABLE (2)</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 7pt">OPTION EXERCISE PRICE</span></td><td style="font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-size: 7pt">OPTION EXPIRATION DATE</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left"><span style="font-size: 7pt">Duane D. Nash, M.D., J.D.</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 9%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"/>
    <td style="width: 9%; text-align: right"><span style="font-size: 7pt"></span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-size: 7pt"></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-size: 7pt"></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-size: 7pt"></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 7pt"></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-size: 7pt">Former Executive Chairman</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">6/5/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">285,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">285,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.77</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">6/5/2035</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">315,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.765</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">12/4/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">300,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.25</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">12/4/2034</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;14,553</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;0.765</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2035&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/17/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">300,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.21</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/17/2034</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/2/2023</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">132,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.40</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/2/2033</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">6/15/2022</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">10,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">6/15/2032</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">3/10/2022</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">75,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">3/10/2032</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">6/10/2021</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">10,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">6/10/2031</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">4/15/2021</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">90,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">4/15/2031</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">10/22/2020</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">120,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">10/22/2030</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">7/2/2020</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">45,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/2/2030</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">7/22/2019</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">29,959</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/22/2029</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 7pt">Daniel Vitt</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-size: 7pt">Chief Executive Officer</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">6/5/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1,558,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.77</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">6/5/2035</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">860,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.765</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">12/4/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">205,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">615,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.25</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">12/4/2034</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">39,732</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.765</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/17/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">555,833</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">604,167</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.21</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/17/2034</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/2/2023</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">218,750</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">81,250</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.40</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/23/2033</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">6/15/2022</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">8,750</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1,250</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">6/15/2032</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/3/2022</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">210,520</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">4,480</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/3/2032</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">3/1/2021</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">115,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">3/1/2031</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">7/2/2020</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">80,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/2/2030</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">8/1/2019</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">65,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">8/1/2029</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 7pt">Andreas Muehler</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-size: 7pt">Chief Medical Officer</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">6/5/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">598,500</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.77</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">6/5/2035</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">330,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.765</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">12/4/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">78,750</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">236,250</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.25</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">12/4/2034</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">15,246</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.765</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/17/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">160,712</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">174,688</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.21</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/17/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/2/2023</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">96,250</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">35,750</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.40</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/2/2033</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">6/15/2022</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">8,750</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1,250</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">6/15/2032</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/3/2022</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">97,916</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">2,084</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/3/2032</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">3/1/2021</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">65,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">3/1/2031</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">7/2/2020</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">44,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/2/2030</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">8/12/2019</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">10,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">8/12/2029</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">8/1/2019</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">30,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">8/1/2029</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 7pt">Glenn Whaley</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-size: 7pt">Chief Financial Officer</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">6/5/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">503,500</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.77</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">6/5/2035</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">280,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.765</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">12/4/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">66,250</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">198,750</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.25</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">12/4/2034</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">12,936</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.765</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/17/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">141,545</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">153,855</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.21</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/17/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/2/2023</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">80,208</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">29,792</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.40</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/2/2033</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">6/15/2022</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">8,750</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1,250</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">6/15/2032</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">3/10/2022</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">37,500</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">2,500</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">3/10/2032</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">1/3/2022</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">68,541</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1,459</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">1/3/2032</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">3/1/2021</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">40,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">3/1/2031</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">7/2/2020</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">30,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/2/2030</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">4/29/2020</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">15,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">4/29/2030</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">12/1/2019</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">15,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.72</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">12/1/2029</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 7pt">Jason Tardio</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-size: 7pt">Chief Operating Officer and President</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">6/5/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">598,500</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.77</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">6/5/2035</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">330,000</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.765</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">12/4/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">39,375</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">118,125</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.25</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">12/4/2034</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">15,246</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">0.765</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/7/2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">7/9/2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">177,104</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">322,896</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">1.25</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">7/9/2034</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(1)</td><td>All options vest 25% on the first anniversary of the vesting commencement date and then in monthly installments over the following
36 months.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(2)</td><td>Stock appreciation rights will vest in full on August 1, 2026.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Perquisites, Health, Welfare and Retirement Benefits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our named executive officers in the U.S. are eligible to participate
in our employee benefit plans, including our medical, dental, vision, group life, disability and accidental death and dismemberment insurance
plans, in each case on the same basis as all of our other employees. We provide a 401(k) savings plan to our employees, including our
current named executive officers, as discussed in the section below entitled &#8220;401(k) Plan.&#8221; Our NEOs in Germany receive health
benefits through the German national healthcare system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We generally do not provide perquisites or personal benefits to our
named executive officers, except in limited circumstances and as noted in the Summary Compensation Table above. Our board of directors
may elect to adopt qualified or non-qualified benefit plans in the future if it determines that doing so is in our best interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>401(k) Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain a tax-qualified retirement plan that provides eligible
U.S. employees, including named executive officers, with an opportunity to save for retirement on a tax advantaged basis. All participants&#8217;
interests in their deferrals are 100% vested when contributed. Pre-tax and after-tax contributions are allocated to each participant&#8217;s
individual account and are then invested in selected investment alternatives according to the participant&#8217;s directions. Currently,
we do not make matching contributions into the plan. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Internal
Revenue Code. As a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable
to the employees until distributed from the 401(k) plan, and all matching contributions, if any, are deductible by us when made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Compensation Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes information about our equity compensation
plans as of December 31, 2025. All outstanding option awards relate to our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="A-24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Plan Category</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities to be issued upon exercise of Outstanding Options, Warrants and Rights (a)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-Average Exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Price of Outstanding Options,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Rights</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(b)</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity compensation plans approved by security holders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-size: 10pt"><i>2021 Employee Stock Purchase Plan<sup>(1)</sup>:</i></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">610,260</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-size: 10pt"><i>2019 Omnibus Equity Incentive Plan, as amended <sup>(2)</sup>:</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,598,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">626,770</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-size: 10pt"><i>Stock Appreciation Rights plans<sup>(3)</sup>: </i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,231,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.765</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,879,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Assumed Vital Equity Compensation Plans:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Equity compensation plans not approved by security holders<i><sup>(4)</sup></i>:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,829,959</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,162,280</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(1)</td><td>At a Special Meeting of Stockholders held on March 4, 2024, our stockholders approved an amendment to our Amended and Restated 2021
Employee Stock Purchase Plan to increase the number of shares of common stock reserved for delivery under such plan by 1,000,000 shares
to a total of 1,200,000 shares.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(2)</td><td>At an Annual Meeting of Stockholders held on June 4, 2025, our stockholders approved an amendment to our 2019 Omnibus Equity Incentive
Plan, as amended, to increase the number of shares of common stock authorized for issuance by 7,000,000 shares to a total of 26,448,871
shares.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(3)</td><td>On July 7, 2025, the Board of Directors of Immunic, Inc. authorized grants, of up to an aggregate of 35,000,000 stock appreciation
rights (&#8220;SARs&#8221;) to the Company&#8217;s employees and executive officers. The SARs are settleable in cash until such time in
which the Company has sufficient number of shares of common stock to support settlement of the SARs with shares. The Company intends to
seek stockholder approval to increase the number of shares available under the Company's 2019 Omnibus Equity Incentive Plan.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>(4)&#160;</td><td>On March 13, 2026, the Board and the Compensation Committee adopted
and approved an Employee Inducement Plan, under which up to 30,000,000 shares of common stock may be issued to eligible persons.</td></tr>
                                                            </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 12. Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the beneficial ownership of our common
stock as of April 16, 2026 by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 20.5pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>each person, or group of affiliated persons, who we know to beneficially own more than 5% of our common stock;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 20.5pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>each of our named executive officers;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 20.5pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>each of our directors; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 20.5pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>all of our executive officers and directors as a group.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The percentage ownership information shown in the table is based on
an aggregate of 136,214,825 shares of our common stock outstanding as of April 16, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have determined beneficial ownership in accordance with the rules
of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment
power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock
options and warrants that are either immediately exercisable or exercisable on or before June 15, 2026 which is 60 days after April 16,
2026. These shares are deemed to be outstanding and beneficially owned by the person holding those options and warrants for the purpose
of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage
ownership of any other person. The table does not include shares of common stock issuable pursuant to the exercise of pre-funded warrants,
which are immediately exercisable and remain exercisable until exercised in full for an exercise price of $0.0001 per share of common
stock. However, under the terms of the pre-funded warrants, a stockholder may not exercise the pre-funded warrants to the extent such
exercise would cause such stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of
common stock which would exceed 9.99% (or for stockholders who so elect, 4.99%) of our then outstanding shares of common stock following
such exercise (excluding for purposes of such determination shares of common stock issuable upon exercise of such pre-funded warrants
which have not been exercised). The amounts set forth in the table below give effect to such beneficial ownership limitations. For each
stockholder in the table below for which such beneficial ownership limitations apply, the number of shares of common stock issuable pursuant
to the exercise of pre-funded warrants held by such stockholder is set forth in the footnote for such stockholder. Unless otherwise indicated,
the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially
owned by them, subject to applicable community property laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise noted below, the address of each of the individuals
and entities named in the table below is c/o Immunic, Inc., 1200 Avenue of the Americas, Suite 200, New York, New York 10036. Beneficial
ownership representing less than 1% is denoted with an asterisk (*).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="text-align: left; font-weight: bold">Number of Shares of Common Stock Beneficially Owned</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold">Percentage of Common Stock Beneficially Owned</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">5% Stockholders:</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>BVF Entities(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">14,648,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">9.99</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Aberdeen Entities(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,196,821</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Janus Entities(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,118,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vivo Entities(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,118,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Adage Entities(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,501,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.10</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Nantahala Entities(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,524,406</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.04</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Commodore Entities(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,454,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.76</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Avidity Entities(8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,426,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.75</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deep Track Entities(9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,454,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.76</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left">Named Executive Officers and Directors:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Duane D. Nash, M.D., J.D.(10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,622,991</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.19</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Tamar Howson(11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Andreas Muehler(12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,018,610</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. J&#246;rg Neermann(13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">505,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Barclay Phillips(14)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Thorvald Nagel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Daniel Vitt(15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.50</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Simona Skerjanec(16)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">233,333,</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Jason Tardio(17)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">283,780</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Glenn Whaley(18)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">658,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Richard Rudick(19)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">503,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Jon Congleton</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">All directors and executive officers as a group and certain former named executive officers (12 people)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,484,972</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5.49</td><td style="border-bottom: Black 1pt solid; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(1)</span></td>
    <td><span style="font-size: 10pt">The amounts include (i) (a) 4,135,956 shares of common stock held by Biotechnology Value Fund, L.P. (&#8220;BVF&#8221;), (b) 6,618,704 shares of common stock issuable upon the exercise of pre-funded warrants within 60 days, up to the holder&#8217;s 9.99% blocker limitation held by BVF (ii) 3,351,749 shares of common stock held by Biotechnology Value Fund II, L.P. (&#8220;BVF2&#8221;), (iii) 473,490 shares of common stock held by Biotechnology Value Trading Fund OS, L.P. (&#8220;Trading Fund OS&#8221;) and (iv) 68,961 shares of common stock held by a certain managed account (the &#8220;Partners Managed Account&#8221; and, together with BVF, BVF2, and Trading Fund OS, the &#8220;BVF Entities&#8221;). The amounts exclude an additional (i) 68,176,762 shares of common stock underlying pre-funded warrants held by the BVF Entities with a 9.99% beneficial ownership limitation. BVF I GP LLC (&#8220;BVF GP&#8221;), as the general partner of BVF, may be deemed to beneficially own the shares beneficially owned by BVF. BVF II GP LLC (&#8220;BVF2 GP&#8221;), as the general partner of BVF2, may be deemed to beneficially own the shares beneficially owned by BVF2. BVF Partners OS Ltd. (&#8220;Partners OS&#8221;), as the general partner of Trading Fund OS, may be deemed to beneficially own the shares beneficially owned by Trading Fund OS. BVF GP Holdings LLC (&#8220;BVF GPH&#8221;), as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the shares beneficially owned in the aggregate by BVF and BVF2. Partners, as the investment manager of each of BVF, BVF2, Trading Fund OS and the Partners Managed Account, and the sole member of Partners OS, may be deemed to beneficially own the shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS and held in the Partners Managed Account. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the shares beneficially owned by Partners. Mark Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the shares beneficially owned by BVF Inc. Pursuant to a certain agreement entered into between Mr. Nagel and Partners, Mr. Nagel is obligated to transfer to Partners the economic benefit received, if any, in connection to his position on the Board of Directors. The business address for each of the entities and Mr. Lampert is 44 Montgomery St., 40th Floor, San Francisco, California 94104.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(2)</span></td>
    <td><span style="font-size: 10pt">The amounts include (i) 8,243,941 shares of common stock and (ii) 5,952,881 shares of common stock issuable upon the exercise of pre-funded warrants within 60 days, up to the holder&#8217;s 9.99% blocker limitation. Exclude an additional 40,807,060 shares of common stock underlying pre-funded warrants and warrants with a 9.99% beneficial ownership limitation. The amounts set forth in the table above give effect to such beneficial ownership limitation. The principal business address of Aberdeen Group plc is 1 George Street, Edinburgh, United Kingdom, EH2 2LL.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(3)</span></td>
    <td><span style="font-size: 10pt">The amounts include 15,118,189 shares of common stock issuable upon the exercise of pre-funded warrants within 60 days, up to the holder&#8217;s 9.99% blocker limitation. Excludes an additional 9,670,811 shares of common stock underlying pre-funded warrants and warrants with a 9.99% beneficial ownership limitation. The amounts set forth in the above table give effect to such beneficial ownership limitations. Such Shares may be deemed to be beneficially owned by Janus Henderson Investors US LLC (&#8220;Janus&#8221;), an investment adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser for the Fund and has the ability to make decisions with respect to the voting and disposition of the shares subject to the oversight of the board of directors of the Fund. Under the terms of its management contract with the Fund, Janus has overall responsibility for directing the investments of the Fund in accordance with the Fund&#8217;s investment objective, policies and limitations. The Fund has one or more portfolio managers appointed by and serving at the pleasure of Janus whom makes decisions with respect to the disposition of the share of Common Stock offered hereby. The address for Janus is 151 Detroit Street, Denver, CO 80206. The portfolio managers for this Fund are: Andrew Acker, Daniel S. Lyons and Agustin Mohedas.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.4pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(4)</span></td>
    <td><span style="font-size: 10pt">The amounts include 15,118,189 shares of common stock issuable upon the exercise of pre-funded warrants within 60 days, up to the holder&#8217;s 9.99% blocker limitation. Excludes an additional 638,203 shares of common stock underlying pre-funded warrants and warrants with a 9.99% beneficial ownership limitation. The amounts set forth in the above table give effect to such beneficial ownership limitations. The principal business address of Vivo Opportunity Cayman Fund, L.P. and Vivo Opportunity Fund Holdings, L.P. is 192 Lytton Avenue, Palo Alto, California 94301.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.4pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.4pt 0pt 0"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.4pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(5)</span></td>
    <td><span style="font-size: 10pt">The amounts include (i) 1,398,600 shares of common stock and (ii) 12,103,000 shares of common stock issuable upon the exercise of pre-funded warrants within 60 days, in each case held by Adage Capital Partners, L.P (&#8220;Adage&#8221;). Bob Atchinson and Phillip Gross are the managing members of Adage Capital Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C., which is the general partner of Adage, and each such person or entity, as the case may be, has shared voting and/or investment power over the securities held by Adage and may be deemed the beneficial owner of such shares, and each such person or entity, as the case may be, disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. The principal business address of Adage Capital Partners LP is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(6)</span></td>
    <td><span style="font-size: 10pt">The amounts include (i) 4,378,406 shares of common stock and (ii) 7,146,000 shares of common stock issuable upon the exercise of pre-funded warrants within 60 days. The principal business address of Nantahala Capital Management, LLC is 130 Main St. 2nd Floor, New Canaan, Connecticut 06840.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.4pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(7)</span></td>
    <td><span style="font-size: 10pt">The amounts include 11,454,000 shares of common stock issuable upon the exercise of pre-funded warrants within 60 days. The principal business address of Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.4pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(8)</span></td>
    <td><span style="font-size: 10pt">The amounts include (i) 6,699,411 shares of common stock and (ii) 5,727,000 shares of common stock issuable upon the exercise of pre-funded warrants. The principal business address of Avidity Private Master Fund I LP is 2828 N Harwood Street, Suite 1220, Dallas, Texas 75201.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(9)</span></td>
    <td><span style="font-size: 10pt">The amounts include 11,454,000 shares of common stock issuable upon the exercise of pre-funded warrants within 60 days. The information herein is based solely on a report on Schedule 13G filed with the SEC on March 4, 2026. The report was filed by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., David Kroin, and Deep Track Special Opportunities Fund, LP., having a principal business address of 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830&#160;&#160;. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(10)</span></td>
    <td><span style="font-size: 10pt">Consists of 36,032 shares of Common Stock and 1,586,959 options to purchase shares of Common Stock within 60 days.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 26.5pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(11)</span></td>
    <td><span style="font-size: 10pt">Consists of options to purchase shares of Common Stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(12)</span></td>
    <td><span style="font-size: 10pt">Consists of 14,406 shares of Common Stock held directly; 60,229 shares held in the Employee Stock Purchase Plan; 204,480 shares of common stock held through Xanomed UG (haftungsbeschr&#228;nkt) and 80,000 shares of common stock held through Xanomed Holding USA, entities controlled by Dr. Muehler; and 659,495 options to purchase shares of common stock within 60 days.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(13)</span></td>
    <td><span style="font-size: 10pt">Consists of 200,000 shares of Common Stock and 305,959 options to purchase shares of Common Stock within 60 days.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(14)</span></td>
    <td><span style="font-size: 10pt">Consists of options to purchase shares of Common Stock within 60 days.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(15)</span></td>
    <td><span style="font-size: 10pt">Consists of 29,000 shares of Common Stock held directly; 362,877 shares of Common Stock held through Listrax UG (haftungsbeschr&#228;nkt), an entity controlled by Dr. Vitt; and 1,654,166 options to purchase shares of Common Stock within 60 days.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 31.85pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(16)</span></td>
    <td><span style="font-size: 10pt">Consists of options to purchase shares of Common Stock within 60 days.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(17)</span></td>
    <td><span style="font-size: 10pt">Consists of 12,512 of shares of common stock and 271,268 options to purchase shares of Common Stock within 60 days.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(18)</span></td>
    <td><span style="font-size: 10pt">Consists of 95,510 of shares of common stock and 563,453 options to purchase shares of Common Stock within 60 days.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">(19)</span></td>
    <td><span style="font-size: 10pt">Consists of 230,375 of shares of common stock and 273,000 options to purchase shares of Common Stock within 60 days.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="A-29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 13. Certain Relationships and Related Transactions, and Director
Independence.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Related Person Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not been a party to any transactions in which the amount involved
exceeded $120,000 and in which any of our executive officers, directors, promoters or beneficial holders of more than 5% of our capital
stock had or will have a direct or indirect material interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnification of Officers and Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered into indemnification agreements with each of our directors
and executive officers. The indemnification agreements, our amended and restated certificate of incorporation and our amended and restated
bylaws require us to indemnify our directors, executive officers and certain controlling persons to the fullest extent permitted by Delaware
law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Related Person Transactions Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We adopted a written Related Person Transactions Policy that sets forth
our policies and procedures regarding the identification, review, consideration, approval and oversight of &#8220;related person transactions.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of our policy only, a &#8220;related person transaction&#8221;
is a past, present or future transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships)
in which we and any &#8220;related person&#8221; are participants, the amount involved exceeds $120,000 and a related person has a direct
or indirect material interest. Various transactions are not covered by this policy, including transactions involving compensation for
services provided to us as an employee, director, consultant or similar capacity by a related person, equity and debt financing transactions
with a related person that are approved by the board, and other transactions not otherwise required to be disclosed under Item 404 of
Regulation S-K. A &#8220;related person&#8221; is any executive officer, director or nominee to become director, a holder of more than
5% of our common stock, including any immediate family members of such persons. Any related person transaction may only be consummated
if approved or ratified by the affirmative vote of seventy-five percent (75%) of our disinterested directors then in office in accordance
with the policy guidelines set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the policy, where a transaction has been identified as a related
person transaction, management must present information regarding the proposed related person transaction to our audit committee for review
and recommendation for approval to our board of directors. In considering related person transactions, our audit committee and board of
directors take into account the relevant available facts and circumstances including, but not limited to whether the terms of such transaction
are no less favorable than terms generally available to an unaffiliated third-party under the same or similar circumstances and the extent
of the related person&#8217;s interest in the transaction. In the event a director has an interest in the proposed transaction, the director
must recuse himself or herself from the deliberations and approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="A-30" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 14. Principal Accountant Fees and Services.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fees Paid to the Independent Registered Public Accounting Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table represents aggregate fees
for services provided to us by Baker Tilly, our principal accountant. All fees below were pre-approved by the audit committee:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left"><span style="font-size: 10pt">Audit Fees <sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">562,017</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">443,768</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit-related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All Other Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">562,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">443,768</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><b>(1)</b></td><td>Includes professional services rendered for the audit of the Company&#8217;s annual financial statements and review of financial
statements included in Forms 10-Q, or services normally provided in connection with statutory and regulatory filings (i.e., attest services
required by Section 404 of the Sarbanes-Oxley Act), services relating to comfort letters and registration statement filings including
out-of-pocket expenses.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Auditor Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2025 and 2024, there were no other professional services provided
by Baker Tilly that would have required our audit committee to consider their compatibility with maintaining the independence of Baker
Tilly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Pre-Approval Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee&#8217;s policy is to pre-approve all audit and
permissible non-audit services provided by the independent accountants. These services may include audit services, audit-related services,
tax services and other services. Our audit committee generally pre-approves particular services or categories of services on a case-by-case
basis. The independent registered public accounting firm and management are required to periodically report to our audit committee regarding
the extent of services provided by the independent registered public accounting firm in accordance with these pre-approvals, and the fees
for the services performed to date. All of the services of Baker Tilly for 2025 and 2024 described above were pre-approved by our audit
committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="A-31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="color: Black">&#160;</span></td>
    <td colspan="5" style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Incorporated by Reference</b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Number</b></p></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt; color: Black"><b>Exhibit Title</b></span></td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: right; width: 5%"><span style="font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: right; width: 8%"><span style="font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="border-top: black 1pt solid; width: 1%">&#160;</td>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: right; width: 15%"><span style="font-size: 10pt"><b>Filing Date</b></span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">1.1</span></td>
    <td style="border-top: black 1pt solid; vertical-align: top"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380525000757/e664551_ex1-1.htm"><span style="font-size: 10pt">Underwriting
    Agreement</span></a></span></td>
    <td style="text-align: right; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">1.1&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">May 30, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">3.1</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm"><span style="font-size: 10pt">Amended
    and Restated Certificate of Incorporation.</span></a></span></td>
    <td style="text-align: right; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">3.1&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">July 17, 2019</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">3.2</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-2.htm"><span style="font-size: 10pt">Third
    Amended and Restated Bylaws.</span></a></span></td>
    <td style="text-align: right; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">3.1&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">July 17, 2019</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">3.3</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001280776/000119380524000341/e619340_8k-immunic.htm"><span style="font-size: 10pt">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Immunic, Inc.</span></a></span></td>
    <td style="text-align: right; vertical-align: top"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">3.1&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">March 8, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.1</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/e618652_ex4-2.htm"><span style="font-size: 10pt">2019
    Omnibus Equity Incentive Plan, as amended</span></a><span style="font-size: 10pt">,</span></span></td>
    <td style="text-align: right; vertical-align: top"><span style="font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">4.2&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">August 21, 2023</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.2+</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380521001075/e620824_s8-immunic.htm"><span style="font-size: 10pt">Amended
    and Restated 2021 Employee Stock Purchase Plan.</span></a></span></td>
    <td style="text-align: right; vertical-align: top"><span style="font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: top">10.3&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">July 28, 2021</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.3*</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><span style="font-size: 10pt">Description
    of Registrant&#8217;s Securities</span></span></td>
    <td style="text-align: right"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">February 26, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.4</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380524000022/e619173_ex4-1.htm"><span style="font-size: 10pt">Form
    of Pre-Funded Warrant</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">January 4, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.5</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380525000454/e664373_ex4-1.htm"><span style="font-size: 10pt">Form
    of Placement Agent Warrant</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">April 9, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.6</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380525000757/e664551_ex4-1.htm"><span style="font-size: 10pt">Form
    of Pre-funded Warrant</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">May 30, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.7</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380525000757/e664551_ex4-2.htm"><span style="font-size: 10pt">Form
    of Series A Warrant</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">May 30, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.8</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380525000757/e664551_ex4-3.htm"><span style="font-size: 10pt">Form
    of Series B Warrant</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">May 30, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.9</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_ex4-1.htm"><span style="font-size: 10pt">Form
    of Pre-funded Warrant</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">February 13, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.10</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_ex4-2.htm"><span style="font-size: 10pt">Form
    of Common Warrant</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">February 13, 2026</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.1+</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1280776/000119380524001079/e663859_8k-immunic.htm"><span style="font-size: 10pt">Addendum No. 6, dated August 29, 2024, to Employment Agreement, dated April 17, 2020, between Immunic, Inc. and Duane Nash.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">September 3, 2024</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.2+</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523001637/e619130_ex10-3.htm"><span style="font-size: 10pt">Employment
    Agreement, dated December 18, 2023, between Immunic, Inc. and Dr. Andreas Muehler.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">December 18, 2023</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.3</span></td>
    <td style="vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380523001637/e619130_ex10-1.htm">Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Daniel Vitt.</a></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">December 18, 2023</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.4</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523001637/e619130_ex10-2.htm"><span style="font-size: 10pt">Fifth
    Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Andreas Muehler.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">December 18, 2023</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.5</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523001637/e619130_ex10-4.htm"><span style="font-size: 10pt">Fifth
    Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Hella Kohlhof.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">December 18, 2023</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.6</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380524000022/e619173_ex10-1.htm"><span style="font-size: 10pt">Securities
    Purchase Agreement, dated January 4, 2024, by and among the Company and the Investors.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">January 4, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">10.7</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-4.htm"><span style="font-size: 10pt">Form
    of Indemnification Agreement.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">July 17, 2019</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.8</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000128077623000004/imux-ex105dienstvertragand.htm"><span style="font-size: 10pt">Service
    Agreement, dated August 22, 2016, between Immunic AG and Dr. Andreas Muehler.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">February 23, 2023</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.9</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000128077623000004/imux-ex106dienstvertragdan.htm"><span style="font-size: 10pt">Service
    Agreement, dated September 29, 2016, between Immunic AG and Daniel Vitt.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">February 23, 2023</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">10.10+</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-5.htm"><span style="font-size: 10pt">Employment
    Agreement between Dr. Daniel Vitt and Immunic AG.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">July 17, 2019</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.11+</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-3.htm"><span style="font-size: 10pt">Employment
    Agreement, dated September 4, 2019, between Immunic, Inc. and Dr. Andreas Muehler.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">99.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">September 5, 2019</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: left; vertical-align: top; width: 10%"><span style="font-size: 10pt">10.12+</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000499/e619564_ex10-2.htm"><span style="font-size: 10pt">Employment
    Agreement dated April 17, 2020, between Immunic, Inc. and Duane Nash.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom; width: 5%"><span style="font-size: 10pt">8-K</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; width: 8%"><span style="font-size: 10pt">10.2</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; width: 15%"><span style="font-size: 10pt">April 20, 2020</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.13+</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-3.htm"><span style="font-size: 10pt">Employment
    Agreement, dated June 10, 2021 between Immunic, Inc. and Dr. Andreas Muehler</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">June 10, 2021</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.14+</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-4.htm"><span style="font-size: 10pt">Employment
    Agreement, dated June 10, 2021 between Immunic, Inc. and Glenn Whaley</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">June 10, 2021</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.15+</span></td>
    <td style="vertical-align: top"><span style="color: Black"><a href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521001455/e621010_ex10-1.htm"><span style="font-size: 10pt">Employment
    Agreement, dated October 14, 2021, between Immunic, Inc. and Patrick Walsh</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">October 14, 2021</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.16+</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000128077625000012/tardioagreementa01.htm">Employee Agreement, dated July 9, 2024, between Immunic, Inc. and Jason Tardio</a></span></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">August 8, 2024</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.17</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1280776/000119380524001496/e664091_8k-immunic.htm"><span style="font-size: 10pt">Employment agreement dated December 13, 2024, between Immunic, Inc. and Dr. Daniel Vitt</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">December 18, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">10.18</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380524000874/e663743_ex4-4.htm"><span style="font-size: 10pt">Amended
    and Restated 2021 Employee Stock Purchase Plan </span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">S-8</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">4.4</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">July 2, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">10.19</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380525000787/e664589_ex10-1.htm"><span style="font-size: 10pt">2019
    Omnibus Equity Incentive Plan, as amended</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">June 4, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">10.20</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380525000454/e664373_ex10-1.htm"><span style="font-size: 10pt">Form
    of Placement Agency Agreement</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">April 9, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">10.21</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380525000454/e664373_ex10-2.htm"><span style="font-size: 10pt">Form
    of Securities Purchase Agreement</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">April 9, 2025</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.22</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380526000007/e665087_ex10-1.htm"><span style="font-size: 10pt">Employment
    Agreement, dated December 29, 2025, between Immunic, Inc. and Dr. Duane Nash.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">January 5, 2026</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.23</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380526000007/e665087_ex10-2.htm"><span style="font-size: 10pt">Employment
    Agreement, dated December 29, 2025, between Immunic, Inc. and Dr. Daniel Vitt.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">January 5, 2026</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.24</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380526000007/e665087_ex10-3.htm"><span style="font-size: 10pt">Addendum
    to Service Agreement, dated December 29, 2025, between Immunic AG and Dr. Daniel Vitt.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10.3</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">January 5, 2026</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.25</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_ex10-1.htm"><span style="font-size: 10pt">Form
    of Securities Purchase Agreement, dated February 12, 2026 by and among Immunic, Inc. and the purchasers named therein.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">February 13, 2026</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.26</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_ex10-2.htm"><span style="font-size: 10pt">Form
    of Registration Rights Agreement, dated February 12, 2026 by and among Immunic, Inc. and the holders named therein.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">February 13, 2026</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">10.27</span></td>
    <td style="vertical-align: bottom"><span style="color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_ex10-3.htm"><span style="font-size: 10pt">Form
    of Purchase and Sale Agreement, dated February 12, 2026 by and among Immunic, Inc., the holders named therein, and BVF Partners,
    L.P.</span></a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10.3</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">February 13, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">19.1</span></td>
    <td style="vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/a19insidertradepolicya04.htm">Immunic, Inc. Insider Trading Policy</a></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">19.1</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">February 22, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">21.1</span></td>
    <td style="vertical-align: bottom"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-123125xexhibit211.htm">List of subsidiaries of the Registrant</a><span style="font-size: 10pt; color: Black"></span></td>
    <td style="text-align: right"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">21.1</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><br/>
February 26, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">23.1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/exhibit23112-31x25.htm">Consent of Baker Tilly U.S. LLP, Independent Registered Public Accounting Firm.</a></span></td>
    <td style="text-align: right">10-K&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">23.1&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 26, 2026</p></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">31.1*</span></td>
    <td style="vertical-align: bottom"><a href="e665391_ex31-1.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">31.2*</span></td>
    <td style="vertical-align: bottom"><a href="e665391_ex31-2.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">32.1**</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-123125xexhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td style="text-align: right"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">32.1</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><br/>
February 26, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">32.2**</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/imux-123125xexhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td style="text-align: right"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">32.2</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><br/>
February 26, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">97</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black"><a href="https://www.sec.gov/Archives/edgar/data/1280776/000128077626000005/a97immunic-clawbackpolic.htm">Immunic, Inc. Clawback Policy.</a></span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">97.1</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">February 22, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.INS*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black">XBRL Instance Document</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.SCH*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black">XBRL Taxonomy Extension Schema Document.</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.CAL*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.DEF*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black">XBRL Taxonomy Extension Definition Linkbase Database.</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.LAB*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black">XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101.PRE*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">104*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt; color: Black">Cover Page Interactive Data File</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-size: 10pt">+</span></td>
    <td><span style="font-size: 10pt">Indicates a management contract or compensatory plan or arrangement.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">*</span></td>
    <td><span style="font-size: 10pt">Filed herewith</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">**</span></td>
    <td><span style="font-size: 10pt">In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="A-33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto
duly authorized.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 50%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 35%">&#160;</td>
    </tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2" style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Immunic, Inc.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 22.5pt"><span style="font-size: 10pt">Date: April 22, 2026</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">By:</span></td>
    <td style="text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">/s/ DANIEL VITT</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; vertical-align: top; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Daniel Vitt</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt"><i>Chief Executive Officer </i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; text-indent: 22.5pt; width: 30%"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="text-indent: 22.5pt; width: 2%">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="text-indent: 22.5pt; width: 2%">&#160;</td>
    <td style="text-align: center; text-indent: 22.5pt; width: 20%"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid">&#160;</td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="border-top: black 1pt solid; text-align: left">&#160;</td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="border-top: black 1pt solid">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ DANIEL VITT</span></td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="text-align: left; padding-left: 0pt"><span style="font-size: 10pt">Director, Chief Executive Officer (principal executive officer)</span></td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">April 22, 2026</span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Daniel Vitt</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ GLENN WHALEY</span></td>
    <td>&#160;</td>
    <td style="text-align: left; padding-left: 0pt"><span style="font-size: 10pt">Chief Financial Officer (principal financial officer and principal accounting officer)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">April 22, 2026</span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Glenn Whaley</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ SIMONA SKERJANEC</span></td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Chair of the Board of Directors</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">April 22, 2026</span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Simona Skerjanec</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ DUANE D. NASH</span></td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">April 22, 2026</span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Duane D. Nash</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ TAMAR HOWSON</span></td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: bottom"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">April 22, 2026</span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Tamar Howson</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ JOERG NEERMANN</span></td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">April 22, 2026</span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Joerg Neermann</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ RICHARD RUDICK</span></td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">April 22, 2026</span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Richard Rudick</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ BARCLAY A. PHILLIPS</span></td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">April 22, 2026</span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Barclay A. Phillips</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ THORVALD NAGEL</span></td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">April 22, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Thorvald Nagel</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="text-align: center; text-indent: 22.5pt">&#160;</td>
    <td style="text-indent: 22.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-indent: 22.5pt">&#160;</td>
    <td style="text-indent: 22.5pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ JON CONGLETON</span></td>
    <td style="text-indent: 22.5pt">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-indent: 22.5pt">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">April 22, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center; text-indent: 22.5pt"><span style="font-size: 10pt">Jon Congleton</span></td>
    <td style="text-indent: 22.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-indent: 22.5pt">&#160;</td>
    <td style="text-indent: 22.5pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 4%"><span style="font-size: 10pt">*By:</span></td>
    <td style="width: 31%"><span style="font-size: 10pt">/s/&#160;<i>Glenn Whaley</i></span></td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">Glenn Whaley</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Attorney-in-Fact</b></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">34</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZF23Hn0WXlipiFSkibgebymA7KZlR2yN5S8cWMQRC8t6XJ0QoNrTWNTJcVkUOJ2zaWjmEAitkNFf0jnS7S8DPAm/aOlbGDesPTMkz6JnlZKH8fXA+tcUygWg+lfFULiGWyWwGx70IvnpKptIlGqdVDcqUcGRqWaNT3I8fTqojQ00/JJ2RrSaTQDyJRvkNMoolHOipXsR3C3meiiAcKhAbpkfrXVnn0HxJyGpsfJwd6X8HH8ulSlw= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e665391_ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Daniel Vitt, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">1.</TD>
    <TD>I have reviewed this Annual Report on Form 10-K/A for the fiscal year ended December 31, 2025 of Immunic, Inc.;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>2.</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>3.</TD>
    <TD>[Omitted];</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>4.</TD>
    <TD>[Omitted]; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>5.</TD>
    <TD>[Omitted].</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: April 22, 2026</FONT></TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 35%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Daniel Vitt</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Daniel Vitt</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e665391_ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Glenn Whaley, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">1.</TD>
    <TD>I have reviewed this Annual Report on Form 10-K/A for the fiscal year ended December 31, 2025 of Immunic, Inc.;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>2.</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>3.</TD>
    <TD>[Omitted];</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>4.</TD>
    <TD>[Omitted]; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>5.</TD>
    <TD>[Omitted].</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: April 22, 2026</FONT></TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 35%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Glenn Whaley</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Glenn Whaley</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>imux-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /KM5s7xRiXgOn8uFZXIsSaSFOcP9wZJ1melBsG17fakavykjoZJNzCbjWAxGcRoL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:IMUX="http://imux.com/20251231" elementFormDefault="qualified" targetNamespace="http://imux.com/20251231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://imux.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="imux-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="imux-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>imux-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>imux-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="imux-20251231.xsd#Cover" roleURI="http://imux.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://imux.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Apr. 16, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">On February 26, 2026, Immunic, Inc., a Delaware Corporation (the &#8220;Company&#8221;)
filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the &#8220;Original Form 10-K&#8221;). The Original
Form 10-K omitted portions of Part III, Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation),
12 (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters), 13 (Certain Relationships and Related
Transactions, and Director Independence), and 14 (Principal Accountant Fees and Services) in reliance on General Instruction G(3) to Form
10-K, which provides that such information may be either incorporated by reference from the registrant&#8217;s definitive proxy statement
or included in an amendment to Form 10-K, in either case filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) not later
than 120 days after the end of the Company&#8217;s fiscal year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunic, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,214,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>35</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="e665391_10ka-immunic.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K/A" isDefinitelyFs="true" isOnlyDei="true" isUsgaap="true" original="e665391_10ka-immunic.htm">e665391_10ka-immunic.htm</File>
    <File>imux-20251231.xsd</File>
    <File>imux-20251231_lab.xml</File>
    <File>imux-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "e665391_10ka-immunic.htm": {
   "nsprefix": "IMUX",
   "nsuri": "http://imux.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "e665391_10ka-immunic.htm"
     ]
    },
    "schema": {
     "local": [
      "imux-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "imux-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imux-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 35,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 60,
   "unitCount": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 35
   },
   "report": {
    "R1": {
     "role": "http://imux.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e665391_10ka-immunic.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e665391_10ka-immunic.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14",
      "r16"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193805-26-000493-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193805-26-000493-xbrl.zip
M4$L#!!0    (  B'EEPS1#;O6\\  *59!P 8    938V-3,Y,5\Q,&MA+6EM
M;75N:6,N:'1M[+UI=]K(M@#Z7;]"+V>XSEN8,'A,NO,6'I(X'0_7N)/N^Z57
M 06H(R2.!CODU[\]5)5*0L+8P0G.\5FGNPU(->S:M>?AE__OR\1WKV44>V'P
MZ_\TZXW_<670#P=>,/KU?SK=PY.3__G_7CN_C!-X#!X-XE^?C9-D^O+%BYN;
MF_I-NQY&HQ?-_?W]%U_PF6?\T,LOI<^U&HWFBS]./W3[8SD1FUX0)R+H2_.2
M[P6?J\?'7\VCO<CW<H_B-WJ2]HNYH>'70?:"_?#."_XQ]VA2^N@V/YKH1[TX
MW&HU=Q>M@Y\P+WRI>K:):X8=RC\.+C]DCR?ESV>/OD@B$<3#,)J(!(X01]K>
M;+0V6SO6()NQ[.<&@L_U47A]ZSA[F^VF'F?N</([Q9][(C80'\@"N/6<\ .\
MT=K6#Z;QYDB(J7EX*.(>#:M^*#X<A;Z,2Y^F7W*/]\,T2*)9^4+4C[D7XBB9
M'QJ^S#UT<OK['^8I;Y)^J??#"3W1; &\\+I(,7CMN/B_7Q(O\>7K7U[P?YU?
M)C(1+KZ\*?^3>M>_/CL,@T0&R>;5; K0Z_.G7Y\E\DOR@N[4"WCK!0_YR_^S
MN>F^\:0_>.EV9?+*/1,3^=+],OCRRCTYHC_^:K2.__J]^Z_6T=M.YP+^@PMS
M-S>7?+F]\Q?N[R^]K[_TOI8?8NN87FHT&\U[O+V]_9<$'(&%P_\[$QD,X)_D
MC2]&?R51*N\PT*$UT%'83VD<+^X+_T\IHC?P3?S7W8"SW:D<\D)&7CC@0=_\
M>8<ACZTACP/ DMDA#!H)_R08R"^_R=E?#2";K;W&[N[.\L/N'  .'/W5_$M1
M(!X?OKK#$*V_NF,120#27T1O>8R8OKO#,$>XD@LU5'MN055C]\+!S(V3F2]_
M?3:$2_'2;3:FB7OE3>"),WGC7H83$=3XBQK,'WE#O'L#[UJ_-O#BJ2]F+]T@
M#"3^YGUYB?=(1G YZ8,W&,@ ;RI^@J?.X$0CK\^W\$MR*8>_/GL3A1-$D\U&
M$_Z?A/1WLT6DT1O [Z*?-/!_[6=N  " >:7W,H>YSUXCZO[R(C?)JJ;=LJ>M
MP/-GK_'U!UK =O4"K%OQ[/6;/Q]H 3OV DKOT+/7V24J6\0+&QEP29$<R@@D
M(1G3[\C=7L8DML#27))%7HXC7"42RDU-YNI?XL$S]7,"]/S79[$WF?H2:;B:
M)C<R3Q6'::1F@H?H/KQ4@."-5@-"<1G]EJ3-ZR_-U]X ?QAZ,G)I$[)4&C@\
M^2T/I^++9K(79;.IN:9TY'-+ 'DL2HY$(E]G.]'C9+\5WX([E+U#.\[F'MAO
MZ*_MV?5W"I25X.W$YT->U,YFN_%X0,I";O(Z6[L97_VR.N#L;#:V-IL[CQ(X
M:NTK DX:> P9X%U%<$RDB--(OE8\[B4\HH?2/^7&Q['*!V=V636^NC;TS#TG
MR'AR<1)@H' $<P#%-XEDBB2,LE_OO/?B\DK&M&8\DD$X\8);YKP5'L5)2X;5
M/]O;+X)1$?",7C/C4"+%+R_@W=>.X_PRU1+(1$0C+WCI@N3R[/6__]'<:;SZ
MY<7TM?W(LK+-*]<:S&V\<A$S-X7OC>"K/EP-&3U[_4OO]>]G)U?'1V[WJG-U
MW/WE1>_U0T_8/3[\_?+DZN2XZW;.CMSC/P[?=<[>'KN'YZ>G)]WNR?G9]UC%
M)Q&/O6"4A/#^4?VP[K8:VUO[.',YV'MA!(>VV0N3))R\= ]\T?_L-F&*./2]
MP2MWU>O3JWA@2'P?''MS?GGJ_A)/14"T!.7\_<8^*3*;FUH"1'WVK[[1!(TJ
M^-?7JS?G[=:LN[7U$23V%0B S6:9!$KZ].MF8_.W%YVBS/?+"US\Z^^!F$81
M<,_"NMLLF_*[XN)WP)"53D% W#@5T6?W/)#/+?@EHN=+F-3WX3#[:+%\UGA&
MGZ=B,-"?[SS[C3=(QOAHXU^O7'4T_=#WQ30&Y5;_15SSET2QCU^2@=EU,BC]
M#OX5J7?TFJYEE'B@)6GX)>'TF7G77OAF['V5O'H !]T[^]>AF'@^J+FWZ,:W
M7=A.$*3"OY33,$K*+^[_[A\=GO7_/NN<;=_[XK*-$?2F+\G+7ACZ$F0Q4(X+
M-[I5=J/M!2*6[>]N[;RJO-KJ/]9QW &DN5_A$I^=_=[YX%X>7YQ?7KD7OU]V
M?^^<7;E7YRYPORM@<6ZS[9Y?NLWMC<%S]_R->_7NV+48HV&*G<,K_+FYW]YB
M3,Y6:1#D!2'VZT=Q.\NG>!-&;C*6[I", .Y,BL@%*B@'+L"RB(9O"FC(-H-C
MUN\J\/"/KW^F_?APZX_[,Q ;#P<PTP3>&P_$#!<K@P(ZMLO0,;?0ZNMUF$91
MSB*S<&M1[VPL]T^GGRZ;*]_:W+9RIJ.J=3Y[?23[<M(#90[5[]+;5G/+[$OJ
MQY]'] FC1\EZE"ZS;ORG4Q08T07EH?MI$0_:NY[%T];7_>O=T2IYT%#X<9$)
ME1HVBZM4C&CK^S"BJ\O.6?>$.,X3,[H;,TK,P;ELZW&'@")N#N3T_D#VPXC<
MH"_=%+A6A$[2;*D$)+@KSOW>?.PT\#"<3+P8XP7<-QX004!W8 TORSC[MKK@
M;)+'I_GA\HO]:6=Z\35\WS[\W%^-5ECB%LC6@);'YF9[I]6HXFG?B6TM8QO8
M6]5,5228H7,I1UZ,UR1!1U[Y*1VT3G=WPW0D&UNK.:7=^5/*K^/9ZY/)) V\
M?LT]"?KU'Z7*;QQ_@2736MUPZ$9FC:Z(W7@J^VBR'K@>@#>)W?Y81/#:\Y]=
MU2_#WO42CA8(.PQNB\66[=%,O-7XUQ(,NGC#=G(W#! XC*:*1W03D*X/.0KE
M,!Q47+@_+KOIA?@[^GUWL IY!V.!T.&6R&D47B,VSVD%>_,W<N&Z44'PQ0VH
M30OO9K48I #<^M>S,DGV!Q_@?NX K\27$^6?ZA,P%G&TW9.X?W;^<??3I]YJ
M:.7^_,E4+.C9Z^V=S59[>V]KJ[WDJ5@*PJVP9_JU%/AO _D&H9,+0EH(4EKD
M_IU&7CSP^B2H :'U;-2CQZ*1"+RO]/EY&5K=!8E6N9&3^F6]6W>/)U,_G,%.
M\N>"YM_GWP7>2VF#JY_K!^'/ HL2WY#.8!#).%;_^0 2>;/\NKX7'Z*S#U\[
MP>5X)=>UU9B_KB6+>?:ZV6HTW,ZU#%(2+5!9Z="T(JZTMRR6M>>G:97OV?]X
MO=\\/I[VOZYFR\UEMMQZ]KJ;>G#I8=_W9!D/>4&6L)3P=+<:2U:$S\=E9WL(
M?YY'5^%-4'ZRIUO;[UN?W_W?\-A;S=&V*H\V6\JSURB^_1E&GZL05\&YL,-&
MV0Z),9Q'%R"G !.H$(_V/PVO)^__$WPX7(T^TFI7;K.P'MCK7$#;DMA[7RQ]
M6#0K)9L7(0B+_O]YTVH)]7_/WU^^$Y_[?PS]U1S!5N41Y%:#SMU&>RZ>;P7B
MS;*BY:TB@5HV4O5I!$CC387ORB^RGR;>-1)[D YD_,U2S,K6"Y!U$;3E@LKC
MMP4ND.^1B'4B*:KQ_/"WWN]?KK[^Y_W;%>%YSKYLSP\GT6ZWGE=@=F7DQ8<0
M0V['8;#0SG9Q^>?6YS\O)LEQ>S7;R-G9BFMX]KJUO;VYO]?<6W!/O\/);V1&
MI7__8Z_5W'T5PW.^G.)2W8#66D-EPT_11.& -BL ''05'HO!%L0JH"R1EWCP
M"ANH9"0'[C2-XA0M54D([[%FU6QM])X;:;.?O%S9&G);6@M;T+?XNQ9:%-JW
M6Q2N,.T'X7PL^F/WT!=Q_(V2@9F]M7W[[)% (+OQ;-(+_8UR3G.?N;=NG_M,
M64HE;EQ^Z8]%,((O O=F[,$W&7Y6<.E5G]JM$E&%1J7NU*S9ZM%A5G@OD@^]
M\:R]U[KZO!JJFK.+%]? ;AB 93<)^Y]K[C\;=;0/N5,1N=?"G\\UN;LS<A4@
M;"H0*C3L$A:6P^_WC^W_/6_LOFU?K@A^.2MF;@'/7F.&VWI J(ADQ^J>5#M@
MQ*>/!X>'7_W?X_M;*8KV8+R=9:;@UGX9$MIK!!(#_.-,Q /Q'T9&%T/U9.)^
M^'"X!(A7+UO^6)XZRO%4]PR$BX=AK-\^W$DP0-.D='LSMS^6<'(3#++T>/F9
MN.1ZL2O<&V#9FY\#T/'=6(H8]C5PO#A.46H2L3N00R]@]]=E"@QOJ[&M 6'!
M#V!2=_^$/U3(Q)PDF[=T?((Y?\,INVK&$YJP_%YT>^/P>##^]+&Q&F-[N\1Z
M5[$@X'7A8B?R?4-F3(SC*D,'OB&$YR$B&>Z&B4&8P#7\3^KA)82[-_1\Z404
MB1.77\HV.@TX%B:[FHO1,.^T^QCZ:9"(B*('HKC"+WYR*';W>D=G)W(UZ%=B
M22TLY GM'@3M;L:2'%&(*9:7?Z/YW!T#I4.$&[C"]UV%=8Z-CCVI'H Q%V"@
M11,U-T6LQ)\Q&LL=P*\@MN.CTTCV)0GQS99+D9RQNP'C 0]WXQ0$Z7@<8JB!
MHX*:DK%(BFN_$?'<I>&7U1Z> Q$/!NY&B_?8 TD ?N_]#3O Y^E1> E7H<;!
M4+B8%D&+%''B[C?<@9C%=6>Q;T+%F7+T' IEB4C2BEO5Z'T\>7M\\7[P9367
MJL2&7;Z<9Z__E%7.EY5>+A 1W&\;:NM5?EV/2]RHN&V(A8" $R]) &6E#X@8
MA0&J@?[,D: 2SMP3E+?A8-&0>B02P>%HA<N8C6'S!EM$ ?:2^NRA[6Y>N1NX
M[=U7K7:K;F08C^)YIAC/8]U,9]F;Z=[A9O)ZZ3).0[A3^N;)^'E]CDV]*<26
M&'@@.!1>5]RK&['7/[D^_]S[>S47J\1K4KZ>[W:QG-5=K"<&:-0 'T:0KNCW
MX4I&\.K 0>1$'2"POW7UMUAZ8[/TAW@"=QEFB33A!<2;P/9FR"QA-. PN-B1
M.XK"FV2L?ZW#7B0MC50.BN=%_XJ#5MU6X]7< M6,]'/SE:L>N_6!RN69!_&.
MJH<+:W74H_I)K10U6[W-EA8!;+Y?_R\TOB[M0M>VUMLMCA_*S_Y.)AVSN=+9
MEKJN<ZZX>7IRAY4LL>_.X]CQ"@*$[FI>.YB+0(\. 4RC,)J5,\:/ET='E^W#
MW_J?[A].,&==H\GI8/IJ\J*AK5WB\LZM%G6]$D)Z#R/F,K[CE2/"SD+47]'A
M=ZM(]CJ!8[&I@;9PD,9>(.,*E6C0G@23]N7A;P?W-S0LE8/;WI['R=SZ[I*"
M6W;W'RA0\38T.2X7+!X(05>%)[LY/-%[>$M;..0=E./+Y1]__-;LGNS\O77_
MJ(7E\N7:)0DWI0N]2\K<(W 0G P7R*L84[#(NID)V [JO*3I G5',R>H@VG,
MLBX<$N=/ER2Q@;B,<_DSG/S&@ZE1B Y@\2'2PFLO)FX1B*#O"1_%(PS=)Z]P
M C*LB :QB[D WL#2DIV<!75#/"\56Y\4K&]6L"[S-@]E750\S T#!]4,D202
M<S;P-.!@,,$()A<CLL*9<!81QT"5J=2(.BPY'$I2P ,5A(9O>JB7!X )>/NC
MT'=#(&\6@F3LDU(8-1HX6XTM*V2D*Z*>@&$WS[_X<D;&RXWFMOM[O8O%=W9;
M.QA?\APWGF&Y<ISU?" ]%AH.O6C"QI$IS"WP(<!<<BX-:,4B'7B)6E?=><*Y
MVZA1G%F7 9IWC02J.144RT;;#%THEXBMP6&1I*EX*O8+\FO*ACSTR;0,7_7#
M*)(FVP,):12A53E$^]JU%Z:Q/]/(4#;K-Q"A*N]C5L,RZ":3Y!@7=&B62:5H
M2UGMN_WQ\6_=P<G7+RM1'A:QVMWRFIM5ZUV:X_ZD=V(Q0I/1"7$W!';+Z)=A
M)=TA)Y(6GA.M,E9;)-;]D$S20)/]6>S%*F\)%;]KN8EEL0?$HV40,Q%'RS'\
M1&XB,[M]<PQ1-\'"#@<+1['M'(I 7KC&BV:6H*0"^Z(KB_96H]YL'&TVX;;?
M^WB<_Q(:>G?#:#R6OF],F!LB=HHA$3GK']#9Y^R#7A$[FW,.Y!6&+BYOH9XP
M_OU+>G&S^_[_+L5#$Z^2!%-[?0O\VM\(K=6[M%>L2F PE1B- +D0^R8<244!
M?1IQ^ASWA\0GF;D -:(A9&4?(G>%]V(G+$9.U%PF0B&SX;X?QDA"I@#:XL@Q
M!7'!'U6!7?#3^S20;KO!57_(A_7/Q>AW04+?&S\4R5_>R5_30;"CL'"GW?CK
MZ]O)Z//'W]Y'5U^SX+\WY#N"R8JH8HWU+(>9A3J^>9S;SV-GD$X&83*0?6\B
M_&>N^B-F@SAH^C C:+-8]Y.&IEJO>^VZJ16A5V<0$Y#0A\\/9,G_]N'. [<#
MQ^V[S1TZMIWY%,)\\!4'F-+)<YW8\S0AA1$0!\\0CV^GL=7<^>OK?T;=[N R
M&=[,_K[]^!:-6WJ>NO1P[CRW&DN>Y\G9&^L<=<7;9GNGUFINU?:RHE5S)ZJ*
MT</ML&]&+M;6H:M9<V] N';#;!]KBP5:4HS=+*.?I9!+799\O8,6U4!6XX$+
M4(-?P=/_27GUW&J"#'A6*X#;ZF[P-)M).'WI[J!71'VA7]@AFYQ9?UEDO#U$
MHV2(1KX&L*H6/+?02(K/FST)R V;F=+F?NSB+%B_0& 3?-<.-2KSO8[_N/C0
M.>M<G5_^Z9Z=7QVOL%#,0U0Z_<5[?2&BQ#TY.8$[:AKR8*7I5=:X6?W2*T+_
M3?G;(QGW(V^*FZF(H#SZFG32Z_;_':PF87FK6=J/PUH'<<4WLA>E C2GEF&,
MN7I#&*N@ZYNXAU8IB@T4FE0 P&'.X?_<83,>VJZX9JE[J>UY[ALX4A>K$IO@
MN?DJF5;!125CV9.=1QY 'MXP0^EYZR2TZ=^=;*I0!T&A98\#)ER-9K!-4&QC
M>-#=./)0ZPTC..9CDZ5ZKA5/-$5J"$CW+2J<:(^1SVMNL^EN9&\<6KKN\YK3
M;+D;.GG /;\)8*RQ-\4U',HH$: @'<@ M"6R[/#O-->IL7'2QTLX!=P$R0[C
MT$?CY"F:1B.,7VRVW0T]'#V)^X1I8OM=AZKW,:./.>91;]G%7B%3A#_O"']K
M;KD;%R9OM\,F2U3YWDC)X\)EN*847E3S0!OW$!YXS&]A1Q&\=!* !)ZR*/1V
MH_T<%7(\%P?/I:9RH93Y75D6*.;+L^[^1,PPEDUZI'UZ!<YM&HIP/;L*.X*.
MEKG&B-+PRRRSH#EAE+/3822/J5FM5NOR:N%7M8@^J!/*6$TNAT)0*X+&> JL
MBG$;"H6[QX<:9\G5@8<3.;![-$=R&*DKAHG2M6$Q6DFQ+AIMR[H[U97!UI-B
M?I*P==</ 41P[[],V2"J0@2KCXO(1IA&1*L<P>1E(B69T@%*<78[8C@;W\]B
MDO&D/ O"\/0<I:D3FD<HQ?JS&@<_%DJ8YY "*9,7Z^@K\Z0Y70^CB=G*CTL
M<4OZ,QCAP?--[1"G8@C4MX4\+25+W9K .%__JE%O;7O!LQ>O*W]:8"?3J6T
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MX%C4V=8+1RJ-*,Q;M$*^.M?3RONZLL5-:=KNO17B]75[P?90D0Q5X0GE93A
MK\(C.)SS-"KQ@&!@8I]+$OHSRML,*4%NZ 9>(-T)60WCNGMU0\XA#,U1C]M>
ME*.H[G[T$M;D\,.9E!$L"=;4DR-!OG(/N!>+J^B"5JZ.1G-?!0L$LA K0'XC
M\I2PE\RT3D@R;<3IR>0&@T=L-PYZJP*7:W2+&-<%HL356$9BZB%XT!;\G%:J
MS,-NYVW.Q65B=BR])_-Q=3&(0A\^ <D PJ&XU3PX(PPG" WLT2.GIO&,ZF3!
M4KO 58PJSH'><.T_Q2A"=-:7!B/X7HQ^,R>K9Z)669*^6,/"]";XB!_(]ICA
M"J 'D%2/PXS(L11)/!LQ&E$EA;Y/Y39R.%5W.PFUN[@E+!=3"NC]/$;J8%U=
M P8#?07OFO:#"\! YUB5Y.U+Y4\L&PMSV1T.;T#0$VK(+U,O6N?T-/3[94Y.
MMFS#:<?JN GQ!+T/?$UIY'VEQ8<J.#[S&B+\J/F(!HNJCL,@U<#03MC"D6T
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M'8M(("<'1)(<AVY*RL)$> '91'3>O&Y-07XT."GQ=Q@I,;JT+T4-3W0@L64
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M(Y ">-9OAO$R0)*-F3D@<E"*(CG0]%%PC1I,>(B(H]DG04!'"D%]:^A$B##
M!8JE#5@=-@G7TYR/=3B./ASW+H<#VCD&":13"A/(NGP@9> R/,0IE9F+F]
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M#HVG(M8MB5$ER2+4+-T  U%59S0[1A$@& R\ 9HI:H681TM!@5,916(2Y\P
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M):NSMF6*3IK:M#2B\AW ,E0]]W([HCOUA2H&"!<(W?W*[$AM<)2GETR#N9=
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M1,U8V-8)K<\9CK-E_IIM:ZU&<[\./-U#(W1(WJHH]*F3P-R$NGN1M6;J#C?
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MTIM@*"+*AB#8AB"8D"8/DL,HH+]4PW?8ANDSC!&/ICQ5+P3=>X*KVD0YQ$.
MIY%$'2@K-:>$[Y[N.ITY%;&BE48G):6I#63UJC+\TO=S$EZ3821TE!)"*E1C
M/X^]/=D'SE$N/U%L'LTWEL)/QGWNQ(0=DJ0N0CA$:>4"GH&S!SG_7?8@2DJ
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M"Z/VHQ!U.6\XE-2(V3*4V3-N<KA*OEN'4=EL;;QS<GJ:#QP]J'\$.>L2P_@
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MQUC--_$QB0A26] 1E5SP'G?DXZ1J'AX#A$:Z2]_<7%EHKHPHPUL)-KZ^)79
M,*BIWK4W2+408>P5HQ 8+&^+&LMAJU?#J^;:D2V\9K1WM/A[RB"_H >LV?&"
M>9RJ0P"F$[C9/:7&MK'P49;D6 =D*OB"#9G<0C*+P(*+0-/$,B%3'7F5AR26
M5T#2GBP!A)6)W912=?G+ILI6V0N#-":T7' UZ^[Y HB@E!*$,.8T3;3! &M=
MJ4@+[5"X#A/5<PU%CUXFR?9">*]8J8ZFK$+9B4"KDL^5T)!ZBS09AQ&2'""!
M H.*S</HU4W@(1=?PF69%]$V-0UO$$:1-4(D551,#TX4Q186PGUQ8WS,1/4C
M!]";MA2K4F@X>2\KN&6J=E4R*5CJS3CTY5H3NV6Z=Y.@:I\!7Q *"#/W*\^X
M\KRA2 *+;521./DP/OK.$Y,G9N*V -4&M$P*["'$3\1G^ %.H$@(' LUN%DQ
M^:"R=L6%1M(@+/N\YKJM:HXX@@6#]T+)"$_BON"E*4NFNL&V^)%'<V=9$'\7
MG'=NPWEW69Q?9DN/X )0K -9,Q!YX;\+&0OBHPQ&%'S:079/K7I-,(53>(T0
MCXS27C2I45=AK %(C6MA$L4GB!_.IE*9$33U)3]S:4=.$>@FU.K>@: ;C#A'
M0TPYU@RS_)R.Q>XS!ERCOJ!THTF*5N75*K8,>$[F&-!<Z*R!$\%HG!\$Z\W<
MN"80D^#'Z2.<]8+I,;9";6>DB BC6>^R<Z.VJ[:F@S*I."<,4#=2DGJI66D8
M+#47)B^"L,%."]Q3EOJHW7O(I0<4C*BVO=RX3 KKE)^X0((!W(G5Y<008B)=
M'8XY*S9@-_*#Y;B'>?^38O%(Y,$Y9:>X4*><<JWKE5T MK&*%:2@RSS]G%)T
M,?T*>LR$VCDCL>3K/%&.PPX*)AW-B"JT2QV\LD#R9"\7XX9*=RR3=6^C'>Q8
MB4M/[1;TJMUC]4BM)D Y_!E(8)^E*@@5WJ#5I:^*Q+(TQZ595>3=8\44H=JU
MLTE;L<C850V^;7G"1+&8ULJ9Y*<&9#9I1T(7"CUGB0L<0K-@<2Q<*;J<#=DG
M2JI(@)^9*T!:XHT '(X/W2CUE>)Y)N*!^,\<2R>J@CG4\%TUUA&::+<V0:C#
MI:*I_SC&"^4(><DVC-P4"4K%)[@&0UAIPLX"0!X@4&N+/DNX]W9^9O=>^\F]
M]T.BPPY!+,<T5?>";O4CL-1^0F873E69<72YH> ?(1D(\M0!&2%Y)13IS54E
M=TB8 58-/U'9/47 B*+5*)YP2AX#3F]!']Z0VL[K6ON43:VYY:("W_26\4DB
MU0PSGZ&# 6OH*60BK6EK-BG[$H@/$RLWH:WT6KMFZ8Y*2,W*G%/E[UC*SUJ$
MOZ:@/66NV60I.L=^3/XAZFY(0Y5L'5*HSJ3,4LC9>\BHF=*3! 2O#@60=WQQ
MXL5 BM%W1#&W:9D)L*9U7!#=.<==Y +KD':K2NL%7F>,AV5%V=U!2MP2!0U*
M?P[0ESF9JAA\1@%<:Q9U8X)[%(\F#RU;OU2O@S1BHS[<G-@N^,P.LRS2> C[
MAA%5B/E$54R@<P(H#_1K5';_1E+:7C3!HBYT?)7[=R@FC%5L1!K#D0&T4PRC
M80S(>V  ,V$LE<O/3Q=$!L891&YUN<@8/U5Y<DH$X<+,8: "K@D%&X_.@W7,
M#H4<?!X/^1L#/2%\"6T[T9!+?&@ZF%&\*8@!4GMVU/VDU@T@?BMC4A\-7/"H
M<K0(:AR![VH'IM9ZT<_EAS'FYF *HW6I5/"95:&5=0)&&&V%ST'\T%A@U4XT
MH2(+B5H+M9Q@+Q4J":#EP&?!-79RDTF/+ \<(8)T)7(#M%+!WS6E1VA;B\%V
MMC4GRNI'.P"L5IO$RW626-F<:634=(OFPLJX>X87P,1H%\\!4;&'G#4>\P6T
M:RKO1\Q4;4?S"]")QEZD;-TJB(1NL3H2 G!-66,4*ZN[G^PEHNS+5APOCE.Y
M>(7D^D //('5J5BK8A/Z>.@P>/N<E\ > GN>FLX=H]-%^FZ&,Q3<C&%M$[.:
M?043>\L\47Y(\BZIR2=2:ELI;H\:36 H([FF\M6AIFD4IRIM )\]@ST?ZSV;
M$-!<SQ&F%AAB2ZBLP)"!' -C,L:M4@L&JL\(0\30>[X-F.XO!E(3VO*;HOMK
M\*$[R@#1%S%;='NR9JZ::=0QC3R."=9=7#"_;C;%. 98*(L I@'(&^S^PC6I
M6-<PCC*[BX? T(<AJ:9>X.#/&-CMGD\"KY?&KB*O)\8MA-'7C*(3ZH>PMDI8
M%^W(:.ZC$F=HJD>.9.+4.)R- XL6;]DI;MG=2+(&/?BC[F6C13W/BNN>DS#Q
MW?/(&U$<CI$L5P3&_7KK88,&CS(1R1*)JEICU(BW>0.BS'Q3@& [<T1+4+WQ
MDN+<)JN;RUCT)*R%8O^'9*0R*49BAI1=)5;BTGQ%+X1Z%?A9-"?/_Z\#=] <
M@>EXH]]&#T\4>/'8C*4EZ,)0>Z 9$!/2[":^E9]22$- <F,82,?>"==.7+@2
MDKMY$6M[_T!BZJ:3";J_<P3P"KG:(Y#-R/U6CI6Q:69U=GP>FTY6\]V?G+D;
MP85$"L7":U9%F;E2WH0JFG.]XE=-MSA^4VES5KS6&&@_;/&52\5$'2Y\:$\S
M7\N3 \!,#&U)I1S[_4+AFU<J[23+3K,?SI*^='3L(](R*N98PL:W^S/;^+:>
M;'PK0<\'ZA-5V1DBUT'BMC81#+KY3A'%YR94/^"5NU1?6$0E16UT[F#6OB'?
MV7-NO%QK3[,JV!O6C/[U6?O92E;X)Q#PA:U,2R:<QT@;7[^)BU(,F>9M[FH&
MW?CG<VI V<O=B'79,JMB*]XR]]!</1RY:W$KU[5XG8!)O317#<LIVCT]ENA6
M//8E7LZ'.*?_CI-Y*"Q?X8CK2'+(4$1ZZ8IAES>=K'CPLL2,G_G&='Q0.= X
M_ 3';UK459@(_Z$W>GNC$I8ORYJU1*/>1JNQ56NU]VJM[>WGE=W*FJU_E8EP
M<^VX\H*E?OE?Y0)E\:FR&<J[UJM7]@JOJ ;V: &H7,J=)_G>J]]I;<-9-![O
M!IJUQE:[UMAK/N(M;#5K.WOMQ[L!<A"UJE>S]AO8:C3A%NP]W@V XE]K-.YV
MC:T>VS^:A-;:33B W=:]#^!;V!)5>2[A1?CU)AILY$LW"&\B,56F!GK@I>L!
MNT4SVOS**JR^"T6%$O%@$4#+&='6HL?*AGN@I>PT2]'Q!ZVF58,':UN[ZP*=
MVQ_\KHLII=T_:#7-G=W:+C8178O5K-5!M6K[*#>WYN2$AZ.,U0+[?R'\GQ;S
MM)BGQ?S(Q:Q0R%O?33XMYFDQ3XOY*1?SL+;3_[^];^UN$\L2_<ZOX&:ZYCHS
M6!:@9Z4J=RF.DSB5V&[;J73/EUE(0A85!&I =MR__NZ]SP$.",F2K >2SZSI
ME"S!>>RSWV<_9OA+*:SH?84BBXYJKS<,EB)GZ(Y.J%:M:O7ZE%MP1ZLQ&RVM
M7BT+;.JZUFHW2K*8LEF@1HE<%Z7B>>T6V*#U*2?=UCUSBSGA/LP*H-P\"RR+
MH\ELM;2:7A8Z;];J6M.0OIW2L\!FL^@Z2IX37C8:.HA.8^JF2/K@Y&+D8N1B
M#GXQT@<G%R,7(Q>SKXO9A0]NJCG]INW/TKB9:E5-+\UJT"'8*(W7JU[3S$:S
M)(LIE_UIU W-*$VTCM[4:L8"6'-4W[1S':S/1DUKM;9H?3[+ U>85;QY[E<6
MQ*D7QV3NRJD#1*7K98%-R?2(,G&_&:&\.[L. 0F^P"7:-K@?WJ$9YI+JA/2]
MR<7(Q<C%',!BI.]-+D8N1BYF7Q>S;=^;6+IJ\V9G:=Q<#5-K3F?T[F@UIMG4
MJNVR!!/4T)HI3P1*F<Q.0\< Q;*@3:EXG:Y5&W6MUMQBYM4:_&Y)@;Z7YWFK
MU>HE<J$T@ 6VZ^5Q]9>(LLK% EOM$F%-J<Y)U_2FOCP22]^;7(Q<C%S, 2Q&
M^M[D8N1BY&+V=3';]KU1C7J5U:C?O.%9%M];73=*Y$21 6][8G@:9ELS2H,V
MI>)U.@"FH34;>^-[N[S,=MW8//,KB]?-J)<I<*G1K&J&7AY??XEHJES,3R]5
MK<!2'92N5<T5L#AF?B?4A^2M@O^W[EY2:8L3L:5)ON7)TE,NT<<D\L<S"TB;
M\/9O6'D[R[R=?]ML&:_>4J,,?.)MX:'Q<:K%A5"?&+N#O>%Z0\N[L]4 >PKZ
M U6OZ(UZHZV>30(?NZ-]N_D;[^W'._M9L#_L4I-]$]M/L1935JA.\'%XM^=[
M" QU;#U2"T9KA%UHJ4&E#<.'2=,J=DA6U[]/1\)TE*+E59NM%1=76]OB:A5J
M487%O=6DT7$\$*P26^F&U#D%A\-5L@;3=1*Y\/F,9F!?\L%XTLWT>/ 4Z !#
M&.8]O7Z6K,YRXZ; 8Y#B6*,=.R*FR#)%8)*X<L1E;(ZXL FW@%-"UT;>ZY,U
MR^ -W+ "_V2$C7('V*24(?/='3;:C7AW5-;V<X"-->_CCIJLC6;<D),> \P1
M6DD#J&RO;P6L+QPVK9WP?N=I _.TI3CU_0YI+!B\<W.J-O46ZR=NA>%DQ.>)
MNX(GI&2YO8G+FY*&Z;:Q>2EV)9R$(9OSPH=GFG%[U,(^V]9X#"O%Y?.>K-AQ
MEO<.G=<;?:K]W71#2-J(L#S>+3@#\EY$#6>!.?@CI\<!S?:++="[P%%L0+U_
MIYVL9S6/3%JAWMMAW$"6^GZ+1Z9E6ZP6/\*W!@PE>2+3195ZBKN/. ?U9LR\
M+AG"4@S!W!Q# +1E7!J07!WZV'3S#EFX_T!$B!B<")4'ZLT=V*[?LSB]XK%_
M\QS\ZP;)19[L<B=;V]S)?HB5'Q3/*-$963,^DV/^K*':%-=/4 ,HNTL-D7MB
MWU)$CM .[K$#,^@PT[6B)#(LA0SUS2*#H,]IXN%B0V /Y6M*]Q5UJR>WYG95
MN=[<V6:[2 WO?&\2[D'#W>\DN$%L4]_VLTO6$-T?HZ8Q\7"GH+2 ;N'%;>%1
MKPELW"=J^3TK'"I=W"M.06W-64]VIB=0OVAJ-@_R.^Y6'\:"/4/IO:1%.YL(
M>\"3;@)J7SHG&$=,4Z$Y$XT&V(22;("TKZEES)J,VCZ#VH/.P(#]"FN-!1)Y
M8IIO0K1.X!U4*9DJ> 26ECV.F H):#XF3<I7AM2&O._<._UDF:\K*O8U/CV[
M!.C_L*<'XPW*9RP1=>& FE;S(V![!S/)GT2IN3;=,%GQL6D7:G$>6&:CT'8'
MA)M]']: &N#80N;BC%&#1<W8>XS55EI6HAX_N3#<M?_@91XL;X_LIYL(MPZY
MB7!=-A'>/M+%JI*6(6(8@%J3)[X<LF,&%F.3%F/&,0-54@:*5#R',/NVC;89
MF)2!/PX<(&\-Z+OG3A@7 >LN<&Q@[<#H!%Z%@Z(<0S8 ;_F!$SDVF\OO_@4S
M V]!WN52"W,%F!;?$&X";$3XKVW!\H4A@1\G''1L!]@RG71^>-2)V%#,DD8&
M GS;PB4A-T5^W'5<D#^E92/G8(;;W6""8A  T="$PR+(HR_+4G6]_DN&8Z<N
M0Q 7!#"4-V)?^JD.\&*>#)V'>'G/W!09=!I;#IE.7ZT AL<7.G"@+DZ$*ZV
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MP-415?]F-+5VH\JB"CB++S.%LF#H^* 6QRC0O(/^%HDT;YC,P2EE(9QJUI_
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M5;K^%T_+64.C34SO'@EU),:)ECV.M6Q6=)5S5T'I9,Q0*5 Z67S8T*+VA#S
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MR*KHQ>T1 @$YC..T+P)KV-?SL?CB'9Y1SQXSI! J'+$BOU-%W=6P9WO UWS
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MZDE23TJH6RI*+UK<2>!(X.R-HK0'KB7=.+SN<U)GDCJ3U)D$ZI;MYUZTY)/
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ME <[9CLCZP<>>]0;,FM(W!C CH^,[%J]A4\<HPD'B"(CV^NS73-D>50G\$4
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M\Y/\!,RA![(\#X1-[KAH>VMVOB3#=D$9QDW:_>,.8 \2S!D'42R<U,W-?16
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MSQUHWH(D("0@-B0F\A U*G6$Z:T/^L53T.?/+@M_>DWM^Y.N:S_S"&8/%?-
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M_._=N7;D>_E%[U6MLT)%[T56?=L )+;+9V;@*C:=$M(\"VN0"-F?]$2/%TO
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M5'NIG[2[/4+P\LFNK""B(DU?^4,=]E#<%]SR^OE430"&AO\8K.OJU&:$T<6
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M.=? B]*J>7!2[FD%E++&+ZF7 ZMX=6H]CM!.3'WFN+VIQXB$8U\3?Q#Y0]L
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M#U'\VI3/S:2BPI0S_ F4M82OI,*1CS!=$*"BGGN)2,4US1&76N$J<.IX7$5
M(JQQ0,IN7!LPHJ!#U[Y'IF7=6\"QT%LX8,444!]T@MYD!!JFAZPPH3!-[4XB
M8B246\NX!YP88S9B\0(B-6'%"N/4JDMY]-8]J+8X(YE3["6>2@4$ERZ([$'@
M2$A4KL,J4@V=H'_,S,6T5$0(JG&&^V;6'Y<X8ZJKPO/_I[D7+W# $XWBTC?I
M)NB$:*![JC.1,K0A$P_Y=Q.,RF FJT? _1.$F_!Y@DESSBBTW0%N! !*'P=@
ME[(7@+*[7-5B.THPBO2V,%P7D1=Z-M9,^3/F6,#I:!RRT[']@IR.YBK7#UM'
M5,$36:M@H@$/A>85")%_?K YB[GAJN,ZW8R;V XM^,IR^K%IG_I((S DDTH\
M5Y,NR.1XJU2@$52;\FYN!CZ@3V;@NZ &D: GP1+87!T(A:*4 X"+@K)ZE@V
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MR!60A0^H%<_&(L9ZX@BA.I@$GA,.X;3H=7(>ABJZ=MF.C(I!YQCY@&^VVL>
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M2'&>[J,L&O3WE!:#6D\74^VY(M.U7?\A5F &H!WX#VABCT&10:,2WN4Z#EN
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M?GY^_#@.!Y\?^HU_M#Y]:DW<&_?A=P:1DZ[??\3_#J.1^_;_ U!+ P04
M"  (AY9<O/8/L0T#  ".#0  $@   &4V-C4S.3%?97@S,2TQ+FAT;=57;6_:
M,!#^/FG_X12ITR9! [3L Z21@- U&@,$T:1JV@>37,!J8D>.*<U^_2X$**5O
M=**:R(>\.'>^Y[D[^\[6E?>C9W_\8%UU6PX](;\LS_5Z7=LRBR?]-5>_K?;
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M_P%02P$"% ,4    "  (AY9<,T0V[UO/  "E60< &               @ $
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M,#(U,3(S,5]L86(N>&UL4$L! A0#%     @ "(>67.(\"GYR!P  7ED  !4
M             ( !RN0  &EM=7@M,C R-3$R,S%?<')E+GAM;%!+!08
.!@ & (L!  !O[      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>e665391_10ka-immunic_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imux-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-04-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2026-04-16</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">true</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-12-31" id="Fact000004">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-12-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000006">0001280776</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="Fact000011">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2025-01-01to2025-12-31" id="Fact000012">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000013">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000014">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-12-31" id="Fact000015">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-12-31" id="Fact000016">001-36201</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000017">Immunic, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-12-31" id="Fact000018">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-12-31" id="Fact000019">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-12-31" id="Fact000020">1200 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-12-31" id="Fact000021">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-12-31" id="Fact000022">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-12-31" id="Fact000023">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000024">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-12-31" id="Fact000025">(332)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-12-31" id="Fact000026">255-9818</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-12-31" id="Fact000027">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-12-31" id="Fact000028">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-12-31" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-01-01to2025-12-31" id="Fact000030">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-01-01to2025-12-31" id="Fact000031">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-12-31" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-12-31" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-12-31" id="Fact000034">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-12-31" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-12-31" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-01-01to2025-12-31" id="Fact000037">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-12-31" id="Fact000038">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000039"
      unitRef="USD">83100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-04-16"
      decimals="INF"
      id="Fact000040"
      unitRef="Shares">136214825</dei:EntityCommonStockSharesOutstanding>
    <dei:AmendmentDescription contextRef="From2025-01-01to2025-12-31" id="Fact000041">On February 26, 2026, Immunic, Inc., a Delaware Corporation (the &#x201c;Company&#x201d;)
filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the &#x201c;Original Form 10-K&#x201d;). The Original
Form 10-K omitted portions of Part III, Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation),
12 (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters), 13 (Certain Relationships and Related
Transactions, and Director Independence), and 14 (Principal Accountant Fees and Services) in reliance on General Instruction G(3) to Form
10-K, which provides that such information may be either incorporated by reference from the registrant&#x2019;s definitive proxy statement
or included in an amendment to Form 10-K, in either case filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) not later
than 120 days after the end of the Company&#x2019;s fiscal year.</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
